Document:

Exhibit 10.104
    

    
      

      

      

      

      

      

      

      

    

    
      STOCK PURCHASE AGREEMENT
by and between
NERVEDA,
      INC.
and
ORE PHARMACEUTICALS INC.
    

    
      

      

      

      Dated as of September 19, 2008
    

    
      

      

      

      

      

      

      

      

      

      

    

    
      
        

        

      

      
        
          - 5 -
        

        
          

        

      

      
        

        

      

    

    
      TABLE OF CONTENTS
    

    
    	
           
        	

        	
          
            Page
          

        
	

        	

        	
           
        
	
          
            ARTICLE I – DEFINITIONS
          

        	
          
            9
          

        
	
           
        	
          
            1.1
          

        	

        	
          
            Certain Defined Terms
          

        	
          
            9
          

        
	
          
            ARTICLE II – PURCHASE AND SALE OF SHARES
          

        	
          
            17
          

        
	

        	
          
            2.1
          

        	

        	
          
            The Stock Purchase
          

        	
          
            17
          

        
	

        	
          
            2.2
          

        	

        	
          
            Closing
          

        	
          
            17
          

        
	

        	
          
            2.3
          

        	

        	
          
            Books and Records
          

        	
          
            17
          

        
	
          
            ARTICLE III – CONSIDERATION
          

        	
          
            17
          

        
	

        	
          
            3.1
          

        	

        	
          
            Consideration for Shares
          

        	
          
            17
          

        
	

        	
          
            3.2
          

        	

        	
          
            Calculation of Final Working Balance
          

        	
          
            17
          

        
	

        	
          
            3.3
          

        	

        	
          
            Adjusted Initial Payment
          

        	
          
            18
          

        
	

        	
          
            3.4
          

        	

        	
          
            Delivery of Shares
          

        	
          
            19
          

        
	
          
            ARTICLE IV – REPRESENTATIONS AND WARRANTIES OF THE SELLER
          

        	
          
            19
          

        
	

        	
          
            4.1
          

        	

        	
          
            Organization, Qualification and Corporate Power
          

        	
          
            19
          

        
	

        	
          
            4.2
          

        	

        	
          
            Enforceability
          

        	
          
            19
          

        
	

        	
          
            4.3
          

        	

        	
          
            Subsidiaries
          

        	
          
            20
          

        
	

        	
          
            4.4
          

        	

        	
          
            No Violations; Consents
          

        	
          
            20
          

        
	

        	
          
            4.5
          

        	

        	
          
            Permits; Compliance with Law
          

        	
          
            20
          

        
	

        	
          
            4.6
          

        	

        	
          
            Capitalization
          

        	
          
            21
          

        
	

        	
          
            4.7
          

        	

        	
          
            Financial Statements; No Undisclosed Liabilities; Internal Controls
          

        	
          
            21
          

        
	

        	
          
            4.8
          

        	

        	
          
            Conduct of Business
          

        	
          
            22
          

        
	

        	
          
            4.9
          

        	

        	
          
            Tangible Assets; Sufficiency of Assets
          

        	
          
            24
          

        
	

        	
          
            4.10
          

        	

        	
          
            Real Property
          

        	
          
            24
          

        
	

        	
          
            4.11
          

        	

        	
          
            Intellectual Property
          

        	
          
            25
          

        
	

        	
          
            4.12
          

        	

        	
          
            Material Contracts
          

        	
          
            29
          

        
	

        	
          
            4.13
          

        	

        	
          
            Intentionally Omitted
          

        	
          
            30
          

        
	

        	
          
            4.14
          

        	

        	
          
            Intentionally Omitted
          

        	
          
            30
          

        
	

        	
          
            4.15
          

        	

        	
          
            Tax Matters
          

        	
          
            30
          

        
	

        	
          
            4.16
          

        	

        	
          
            Legal Proceedings
          

        	
          
            32
          

        
	

        	
          
            4.17
          

        	

        	
          
            Employee Benefits
          

        	
          
            32
          

        
	

        	
          
            4.18
          

        	

        	
          
            Employees
          

        	
          
            33
          

        

    

    
      
        

        

      

      
        
          - 6 -
        

        
          

        

      

      
        

        

      

    

    
    	
          
             
          

        	
          
            4.19
          

        	
           
        	
          
            Environmental Matters
          

        	
          
            34
          

        
	

        	
          
            4.20
          

        	

        	
          
            Related Party Transactions
          

        	
          
            35
          

        
	

        	
          
            4.21
          

        	

        	
          
            Insurance
          

        	
          
            35
          

        
	

        	
          
            4.22
          

        	

        	
          
            Minute Books
          

        	
          
            35
          

        
	

        	
          
            4.23
          

        	

        	
          
            Brokers’ Fees
          

        	
          
            35
          

        
	

        	
          
            4.24
          

        	

        	
          
            Accounts Receivable
          

        	
          
            36
          

        
	

        	
          
            4.25
          

        	

        	
          
            FDA Compliance
          

        	
          
            36
          

        
	

        	
          
            4.26
          

        	

        	
          
            Healthcare Compliance
          

        	
          
            36
          

        
	

        	
          
            4.27
          

        	

        	
          
            Intentionally Omitted
          

        	
          
            37
          

        
	

        	
          
            4.28
          

        	

        	
          
            Projections; Other Representations
          

        	
          
            37
          

        
	

        	
          
            4.29
          

        	

        	
          
            Representations Complete
          

        	
          
            37
          

        
	
          
            ARTICLE V – REPRESENTATIONS AND WARRANTIES OF THE PURCHASER
          

        	
          
            37
          

        
	

        	
          
            5.1
          

        	

        	
          
            Organization, Qualification and Corporate Power
          

        	
          
            37
          

        
	

        	
          
            5.2
          

        	

        	
          
            Enforceability
          

        	
          
            37
          

        
	

        	
          
            5.3
          

        	

        	
          
            No Violations; Consents
          

        	
          
            38
          

        
	

        	
          
            5.4
          

        	

        	
          
            Compliance with Law
          

        	
          
            38
          

        
	

        	
          
            5.5
          

        	

        	
          
            Brokers’ Fees
          

        	
          
            39
          

        
	

        	
          
            5.6
          

        	

        	
          
            Litigation
          

        	
          
            39
          

        
	

        	
          
            5.7
          

        	

        	
          
            Independent Investigation
          

        	
          
            39
          

        
	

        	
          
            5.8
          

        	

        	
          
            Financial Statements; No Undisclosed Liabilities
          

        	
          
            39
          

        
	

        	
          
            5.9
          

        	

        	
          
            Financing
          

        	
          
            40
          

        
	

        	
          
            5.10
          

        	

        	
          
            Solvency
          

        	
          
            40
          

        
	

        	
          
            5.11
          

        	

        	
          
            No Material Adverse Effect
          

        	
          
            40
          

        
	
          
            ARTICLE VI – CONDITIONS TO CLOSING
          

        	
          
            40
          

        
	

        	
          
            6.1
          

        	

        	
          
            Closing Deliverables to the Purchaser
          

        	
          
            40
          

        
	

        	
          
            6.2
          

        	

        	
          
            Closing Deliverables of the Purchaser
          

        	
          
            41
          

        
	
          
            ARTICLE VII – COVENANTS
          

        	
          
            41
          

        
	

        	
          
            7.1
          

        	

        	
          
            Post-Closing Covenants
          

        	
          
            41
          

        
	

        	
          
            7.2
          

        	

        	
          
            Non-Competition Agreement
          

        	
          
            49
          

        
	

        	
          
            7.3
          

        	

        	
          
            Employee Non-Solicitation Agreement
          

        	
          
            49
          

        
	

        	
          
            7.4
          

        	

        	
          
            Miscellaneous
          

        	
          
            49
          

        
	
          
            ARTICLE VIII – SURVIVAL OF REPRESENTATIONS, WARRANTIES AND
          

        	
          
            50
          

        
	

        	
          
            COVENANTS; INDEMNIFICATION
          

        	

        

    

    
      
        

        

      

      
        
          - 7 -
        

        
          

        

      

      
        

        

      

    

    
    	
           
        	
          
            8.1
          

        	
           
        	
          
            Survival
          

        	
          
            50
          

        
	

        	
          
            8.2
          

        	

        	
          
            Seller’s Indemnification
          

        	
          
            50
          

        
	

        	
          
            8.3
          

        	

        	
          
            Purchaser’s Indemnification
          

        	
          
            51
          

        
	

        	
          
            8.4
          

        	

        	
          
            Claims
          

        	
          
            51
          

        
	

        	
          
            8.5
          

        	

        	
          
            Limitations; Exclusive Remedy; Effect of Investigation; Waiver
          

        	
          
            53
          

        
	
          
            ARTICLE IX – MISCELLANEOUS
          

        	
          
            54
          

        
	

        	
          
            9.1
          

        	

        	
          
            Expenses
          

        	
          
            54
          

        
	

        	
          
            9.2
          

        	

        	
          
            Publicity
          

        	
          
            54
          

        
	

        	
          
            9.3
          

        	

        	
          
            Notices
          

        	
          
            54
          

        
	

        	
          
            9.4
          

        	

        	
          
            Headings
          

        	
          
            55
          

        
	

        	
          
            9.5
          

        	

        	
          
            Seller Deliverables
          

        	
          
            55
          

        
	

        	
          
            9.6
          

        	

        	
          
            Entire Agreement; Amendments
          

        	
          
            55
          

        
	

        	
          
            9.7
          

        	

        	
          
            Severability
          

        	
          
            55
          

        
	

        	
          
            9.8
          

        	

        	
          
            Waiver
          

        	
          
            55
          

        
	

        	
          
            9.9
          

        	

        	
          
            Binding Effect; Assignment
          

        	
          
            56
          

        
	

        	
          
            9.10
          

        	

        	
          
            No Third Party Beneficiaries
          

        	
          
            56
          

        
	

        	
          
            9.11
          

        	

        	
          
            Specific Performance
          

        	
          
            56
          

        
	

        	
          
            9.12
          

        	

        	
          
            Counterparts
          

        	
          
            56
          

        
	

        	
          
            9.13
          

        	

        	
          
            Governing Law
          

        	
          
            56
          

        
	

        	
          
            9.14
          

        	

        	
          
            Consent to Jurisdiction and Venue
          

        	
          
            56
          

        
	

        	
          
            9.15
          

        	

        	
          
            Waiver of Jury Trial
          

        	
          
            57
          

        
	

        	
          
            9.16
          

        	

        	
          
            Other Remedies
          

        	
          
            57
          

        
	

        	
          
            9.17
          

        	

        	
          
            Interpretation
          

        	
          
            57
          

        
	

        	
          
            9.18
          

        	

        	
          
            Rules of Construction
          

        	
          
            57
          

        

    

    
      
        

        

      

      
        
          - 8 -
        

        
          

        

      

      
        

        

      

    

    
      STOCK PURCHASE AGREEMENT
    

    
      This Stock Purchase Agreement (this “Agreement”), is
      made and entered into as of September 19, 2008, by and between Nerveda,
      Inc., a Delaware corporation (the “Purchaser”) and
      Ore Pharmaceuticals Inc., a Delaware corporation (the “Seller”).  Certain
      capitalized terms in this Agreement have the meanings ascribed thereto
      in Section 1.1.
    

    
      RECITALS
    

    
      A.  The Board of Directors of the Purchaser and the Board of Directors
      of the Seller believe it is advisable and in the best interest of each
      entity and their respective stockholders that the Seller sell to
      Purchaser and the Purchaser acquire all issued and outstanding capital
      stock of DioGenix Inc., a Delaware corporation (the “Company”)
      pursuant to the terms hereof.
    

    
      B.  The Seller is the owner of all of the issued and outstanding capital
      stock of the Company.
    

    
      C.  The Seller desires to sell, and the Purchaser desires to purchase,
      all of the issued and outstanding capital stock of the Company (the “Stock
      Purchase”) upon the terms and subject to the conditions set
      forth herein.
    

    
      D.  The Seller and the Purchaser desire to make certain representations,
      warranties, covenants and other agreements in connection with the
      transactions contemplated herein.
    

    
      E.  Concurrently with the execution and delivery of this Agreement, and
      as a condition and inducement to the Purchaser to enter into this
      Agreement, (i) each of the Business Employees (as defined below) shall
      have entered into an “at-will” employment arrangement with the Company
      to be effective as of the Closing Date pursuant to his or her execution
      of an offer letter and a proprietary information and inventions
      assignment agreement, each on the Purchaser’s standard form; (ii) each
      of the Business Employees shall have executed and delivered to the
      Purchaser a Non-Competition Agreement (as defined below) substantially
      in the form attached hereto as Schedule A; and (iii) each of
      the Business Employees shall have executed and delivered a resignation,
      waiver and release letter (each, a “Resignation Letter”),
      substantially in the form attached hereto as Schedule B, to the
      Seller.
    

    
      F.  The Seller and the Purchaser have approved this Agreement and the
      Stock Purchase as required by Purchaser Applicable Law and Seller
      Applicable Law (each as defined below).
    

    
      AGREEMENT
    

    
      NOW THEREFORE, in consideration of the mutual agreements and respective
      representations, warranties and covenants set forth herein and for other
      good and valuable consideration, the receipt and sufficiency of which is
      hereby acknowledged, the parties agree as follows:
    

    
      ARTICLE I   – DEFINITIONS
    

    
      1.1  Certain Defined Terms
    

    
      Unless the context requires otherwise, the following terms shall have
      the respective meanings specified below (such meanings to be equally
      applicable to the singular and plural forms of the terms defined):
    

    
      
        

        

      

      
        
          - 9 -
        

        
          

        

      

      
        

        

      

    

    
      “Accounting Firm” is defined in Section 7.1(a)(vii).
    

    
      “Actions” is defined in Section 4.16.
    

    
      “Adjusted Initial Payment” is defined in Section 3.3(b).
    

    
      “Affiliate” means, with respect to a specified
      Person, any Person who directly or indirectly Controls, is Controlled by
      or is under common Control with the specified Person.
    

    
      “Agreement” is defined in the introductory paragraph.
    

    
      “Arbitrator” is defined in Section 3.2.
    

    
      “Balance Sheet Date” means September 12, 2008, the
      date of the most recent unaudited balance sheet included in the
      Financial Statements.
    

    
      “Benefit Plan” means any “employee
      benefit plan,” as that term is defined in Section 3(3) of ERISA, and any
      other employment, bonus, pension, profit sharing, deferred compensation,
      phantom stock, stock option or other (other than at will offer letters
      that do not provide for any severance or termination benefits)
      equity based award, severance, disability, change-in-control, vacation,
      commission, welfare, fringe benefit or other material benefit plan,
      agreement, policy, program or arrangement (whether written or unwritten,
      funded or unfunded) sponsored or maintained by the Company, the Seller
      or any ERISA Affiliate for the benefit of any Business Employee.
    

    
      “Business” means the molecular diagnostic business
      unit of the Company and the Seller, to the extent that Seller operates
      the Business, directed to autoimmune neurodegenerative conditions, as
      currently conducted.
    

    
      “Business Day” means any day that is not a Saturday,
      a Sunday or any other day on which banks generally are required or
      authorized to be closed in Gaithersburg, Maryland.
    

    
      “Business Employees” shall mean the individuals
      listed on Schedule C hereto.
    

    
      “Cap” is defined in Section 8.5(b).
    

    
      “Claim” is defined in Section 8.4(a).
    

    
      “Claim Notice” is defined in Section 8.4(a).
    

    
      “Clinical Subject Protected Health Information”
      means data in the possession of the Company that, to the extent it
      relates to an individual patient or clinical subject, is protected by
      the Health Insurance Portability and Accountability Act of 1996.
    

    
      “Closing” is defined in Section 2.2.
    

    
      “Closing Date” is defined in Section 2.2.
    

    
      “COBRA” means the Consolidated Omnibus Budget
      Reconciliation Act of 1985, as amended, and any similar and applicable
      state statute.
    

    
      “Code” means the Internal Revenue Code of 1986, as
      amended.
    

    
      “Company” is defined in Recital A.
    

    
      “Company Confidential Information” is defined in Section
      4.11(i).
    

    
      “Company Intellectual Property” is defined in Section 4.11(g).
    

    
      “Company Office Space” is defined in Section
      4.10(c).
    

    
      “Company Permits” is defined in Section 4.5(b).
    

    
      “Company Products” means all products and services
      developed (including products and services for which development is
      substantially completed), manufactured, made commercially available,
      marketed, distributed, sold, imported for resale or licensed out by or
      on behalf of the Company since acquired by the Seller.
    

    
      “Company’s Registered Intellectual Property”
      is defined in Section 4.11(a).
    

    
      “Contract” means any mortgage, indenture, lease,
      contract, agreement, instrument, obligation or any other commitment,
      whether oral or written.
    

    
      
        

        

      

      
        
          - 10 -
        

        
          

        

      

      
        

        

      

    

    
      “Control” means the possession, directly or
      indirectly, of the power to direct the management and policies of a
      Person, whether through ownership of voting securities or otherwise.
    

    
      “Current Balance Sheet” means the unaudited balance
      sheet of the Company dated as of the Balance Sheet Date.
    

    
      “Deductible Basket” is defined in Section 8.5(b).
    

    
      “Delayed Payment” is defined in Section
      3.1(b).
    

    
      “Dispute Notice” is defined in Section 3.2.
    

    
      “Due Date” is defined in Section
      7.1(d)(viii)(B).
    

    
      “Environmental Law(s)” means all federal, state and
      local statutes, regulations, directives, codes, and policies having the
      force of law, and all court orders, decrees and arbitration awards, and
      the common law, relating to pollution or protection of the environment,
      natural resources or worker health and safety, including, those related
      to the use, handling, transport, treatment, recycling, labeling,
      manufacture, exposure of others to, sale, or disposal, release or
      discharge of Hazardous Materials or any product or waste containing a
      Hazardous Material.
    

    
      “Environmental Permits” means all approvals,
      permits, registrations, certifications, licenses, clearances or consents
      required to be obtained from any Governmental Authority required under
      or issued pursuant to any Environmental Law.
    

    
      “ERISA” means the Employee Retirement Income
      Security Act of 1974, as amended.
    

    
      “ERISA Affiliate” means any Subsidiary of the Seller
      and any other person that, together with the Seller, would be deemed a
      “single employer” within the meaning of Sections 414(b), (c), (m) or (o)
      of the Code.
    

    
      “FDA” shall mean the United States Federal Food and
      Drug Administration or other foreign or state health and drug regulatory
      authorities.
    

    
      “Final Working Balance” is defined in Section 3.2.
    

    
      “Financial Records” is defined in Section 7.1(g).
    

    
      “Financial Statements” means the unaudited balance
      sheet of the Company and the related unaudited statements of income as
      of and for the seven (7) months ended July 31, 2008.
    

    
      “First Commercial Sale” means, with respect to any
      Royalty Product or Royalty Service, the first sale for use or
      consumption by the general public of such Royalty Product or Royalty
      Service.
    

    
      “Forms” is defined in Section
      7.1(d)(viii)(B).
    

    
      “Funded Indebtedness” means, without duplication,
      the aggregate amount (including the current portions thereof) of all
      (a) indebtedness for money borrowed from others, letters of credit and
      purchase money indebtedness (other than accounts payable in the ordinary
      course) of the Company (including any such obligations that are not full
      recourse to the Company but are secured by assets of the Company);
      (b) obligations of the Company evidenced by bonds, debentures, notes or
      similar instruments; (c) all obligations under leases of the Company
      that are required to be reflected as capital lease obligations on the
      consolidated balance sheet of the Company by GAAP; (d) all inter-company
      debt of the Company to the Seller or any Affiliate of the Seller; and
      (e) all guarantees or other direct or indirect assurances of payment by
      the Company of any of the foregoing types of indebtedness owed by any
      other Person.  Funded Indebtedness shall not include outstanding,
      uncashed checks or drafts on Company bank accounts.
    

    
      “Funding” is defined in Section 7.1(b)(i).
    

    
      “GAAP” means United States generally accepted
      accounting principles as in effect from time to time, consistently
      applied.
    

    
      
        

        

      

      
        
          - 11 -
        

        
          

        

      

      
        

        

      

    

    
      “Governmental Authority” means any government,
      governmental or regulatory authority, agency, instrumentality,
      department, court, commission, body, tribunal or other governmental
      entity, whether foreign or domestic and whether national, federal,
      state, provincial or local.
    

    
      “Hazardous Materials” means (a) any petroleum
      products, by-products or breakdown products, radioactive materials,
      friable asbestos-containing materials and polychlorinated biphenals; (b)
      all chemical, material or substance defined or regulated as toxic or
      hazardous or as a pollutant or contaminant or waste; (c) any radioactive
      substances, elements or compounds; or (d) any biological pathogens,
      viruses or harmful biological substances under any applicable
      Environmental Law.
    

    
      “Indemnified Party” is defined in Section 8.3(a).
    

    
      “Indemnifying Party” is defined in Section 8.4(a).
    

    
      “Initial Capital Commitment” is defined in Section
      7.1(b)(ii).
    

    
      “Initial Payment” is defined in Section 3.1(a).
    

    
      “Intellectual Property” means all United States and
      foreign trademarks, service marks, trade names, slogans, logos, trade
      dress, and other similar designations of source or origin, together with
      all goodwill, registrations and applications related to the foregoing;
      patents, utility, models and industrial design registrations and
      applications therefor (including, without limitation, any continuations,
      divisionals, continuations-in-part, provisionals, extensions, renewals,
      reissues, re-examinations and applications for any of the foregoing and
      foreign counterparts thereof), and patent and invention disclosures;
      copyrights and copyrightable subject matter (including, without
      limitation, any registration and applications for any of the foregoing);
      databases (including gene expression and biomarker databases) and other
      information assets; relationships with clinical centers; access to
      biorepositories; mask works rights and trade secrets and other
      confidential business information (including manufacturing and
      production processes and techniques, research and development
      information, technology, drawings, specifications, designs, plans,
      proposals, technical data and know-how, financial, marketing and
      business data and know-how, pricing and cost information, business and
      marketing plans, customer and supplier lists and information, where
      confidential), and computer programs (whether in source code, object
      code or other form); World Wide Web addresses and domain registrations.
    

    
      “Internal Controls” is defined in Section 4.7(c).
    

    
      “Leased Real Property” means all real property,
      land, buildings, improvements and structures leased, subleased or
      occupied by the Company or that will be used solely for the benefit of
      the Company immediately following the Closing.
    

    
      “Liabilities” is defined in Section 4.7(b).
    

    
      “Lien” means any mortgage, pledge, lien,
      encumbrance, charge or other security interest, restriction, equitable
      interest, option, easement, exception to title of any kind, restriction
      or third-party right or encumbrance of any nature.
    

    
      “Losses” is defined in Section 8.2(a).
    

    
      “Material Adverse Effect” means any change,
      development, fact, condition, event, occurrence or effect with respect
      to the Company or the Business, taken as a whole, that, individually or
      in the aggregate, would reasonably be expected to have a material
      adverse effect on the assets, business, properties, operations,
      condition (financial or otherwise) or results of operations of the
      Company or the Business, taken as a whole, or would reasonably be
      expected to materially delay or prevent the consummation of the
      transactions contemplated by this Agreement; provided, however,
      that none of the following Effects shall constitute a Material Adverse
      Effect or Material Adverse Change: (a) any Effects to the extent
      directly resulting from the announcement of the transactions
      contemplated by this Agreement or the satisfaction of the parties’
      respective obligations set forth herein, (b) any Effects to the extent
      directly resulting from the identity of the Purchaser, (c) changes in
      the general economic conditions or political climate in the United
      States or any region where the Business operates, (d) changes in the
      U.S. or global financial or banking markets (including any disruption
      thereof), (e) changes generally applicable to the industries in which
      the Business is conducted, (f) changes after the date hereof in laws,
      rules and regulations applicable to the Company or the Business,
      including changes in accounting principles and (g) any natural
      disasters, acts of war, terrorism, sabotage or other “acts of God,”
      except, with respect to clauses (c), (d), (e) and (f), to the extent
      that the Effects are materially disproportionately adverse to the
      Company or the Business, taken as a whole, as compared to other
      companies in the industry in which the Business operates.
    

    
      
        

        

      

      
        
          - 12 -
        

        
          

        

      

      
        

        

      

    

    
      “Material Contracts” is defined in Section 4.12(a).
    

    
      “M&A Qualified Beneficiaries” is defined in Section
      7.1(c)(ii).
    

    
      “Net Sales” means, (a) with respect to any Royalty
      Product, the invoiced sales price of such Royalty Product billed to
      independent customers who are not Affiliates, less (i) credits,
      allowances, discounts and rebates to, and chargebacks from the account
      of, such independent customers for spoiled, damaged, out dated, rejected
      or returned Royalty Product; (ii) actual freight and insurance costs
      incurred in transporting such Royalty Product to such customers; (iii)
      cash, quantity and trade discounts and other price reductions; (iv)
      sales, use, value added and other direct taxes incurred; and (v) customs
      duties, surcharges and other governmental charges incurred in connection
      with the exportation or importation of such Royalty Product, and (b)
      with respect to any Royalty Service, the invoiced sales price of such
      Royalty Service billed to independent customers who are not Affiliates,
      less (i) credits, allowances, discounts and rebates to, and chargebacks
      from the account of, such independent customers for rejected Royalty
      Services; (ii) actual costs incurred in performing such Royalty Services
      for such customers; (iii) cash, quantity and trade discounts and other
      price reductions; (iv) sales, use, value added and other direct taxes
      incurred; and (v) customs duties, surcharges and other governmental
      charges incurred in connection with the performance of such Royalty
      Services.
    

    
      “Non-Competition Agreement” shall mean in the
      agreement in the form attached hereto as Schedule A.
    

    
      “Note” is defined in Section 3.1(b).
    

    
      “Office Actions” is defined in Section
      4.11(d).
    

    
      “Open Source Code” means any software code that is
      distributed as “open source software” or is otherwise distributed or
      made generally available in source code form under license terms that
      permit modification and redistribution of such software in source code
      form.
    

    
      “Ordinary Course of Business” means in the ordinary
      course of the Business as conducted by the Seller and the Company,
      consistent with past practice.
    

    
      “Overpayment Amount” is defined in Section
      3.3(b).
    

    
      “Owned Real Property” means any real property, land,
      buildings, improvements and structures owned by the Company.
    

    
      “Permits” means licenses, permits, authorizations,
      product qualifications, registrations, certificates, consents,
      accreditations, approvals and franchises, membership affiliations,
      rights, approvals and orders of any Governmental Authority, other than
      the Environmental Permits.
    

    
      “Permitted Liens” means (a) any restriction on
      transfer arising under applicable securities laws, (b) Liens for current
      Taxes or other governmental charges not yet due and payable,
      (c) mechanics’, carriers’, workers’, repairers’, landlords’ and similar
      statutory Liens arising or incurred in the Ordinary Course of Business
      for sums not yet due, and (d) Liens the existence of which, individually
      and in the aggregate, would not reasonably be expected to materially
      impair the continued use and operation of the assets to which they
      relate in the conduct of the Business as currently conducted.
    

    
      
        

        

      

      
        
          - 13 -
        

        
          

        

      

      
        

        

      

    

    
      “Person” means an individual, partnership,
      corporation, limited liability company, association, joint stock
      company, trust, joint venture, unincorporated organization, any other
      business entity, or a Governmental Authority.
    

    
      “Post-Closing Financial Statements” is defined in Section 7.1(g).
    

    
      “Pre-Closing Employee Liabilities” means any
      liabilities arising out of or related to any “employee benefit plan”
      (within the meaning of Section 3(3) of ERISA) or severance pay policy
      maintained by the Seller or any of its ERISA Affiliates prior to the
      Closing Date for the benefit of any Business Employee.  
    

    
      “Pre-Closing Tax Period” means any Tax period of the
      Company ending on or prior to the Closing Date, including the portion of
      any Straddle Period that ends on the Closing Date.
    

    
      “Proposed Final Working Balance Statement” is
      defined in Section 3.2.
    

    
      “PTO” is defined in Section 7.1(c)(i).
    

    
      “Purchase Price” is defined in Section 3.1.
    

    
      “Purchaser” is defined in the introductory paragraph.
    

    
      “Purchaser Applicable Law” is defined in Section
      5.4.
    

    
      “Purchaser Financial Statements” is defined in Section 5.8(a).
    

    
      “Purchaser Indemnified Parties” is defined in Section
      8.2(a).
    

    
      “Purchaser Liabilities” is defined in Section 5.8(b).
    

    
      “Related Parties” is defined in Section 4.20.
    

    
      “Representatives” means, with respect to any Person,
      that Person’s officers, directors or managers, employees, counsel,
      accountants, investment bankers, agents and others who act on such
      Person’s behalf in connection with the evaluation (including due
      diligence), negotiation, execution, effectuation or consummation of the
      transactions contemplated by this Agreement.
    

    
      “Resignation Letter” is defined in Recital E.
    

    
      “Restricted Period” is defined in Section 7.2.
    

    
      “Royalty Consideration” is defined in Section
      7.1(a)(i).
    

    
      “Royalty Field” means non-invasive molecular
      diagnosis of multiple sclerosis in humans.
    

    
      “Royalty Products” means any products for use in the
      Royalty Field, which if made, offered for sale, sold, used or imported
      would infringe one or more Valid Claims.
    

    
      “Royalty Services” means any services performed in
      the Royalty Field which (a) use or employ Royalty Products, or (b) if
      performed, would infringe one or more Valid Claims.
    

    
      “Royalty Term” means, with respect to each Royalty
      Product or Royalty Service in each country, if the manufacture, use or
      sale of such Royalty Product, or the performance of such Royalty
      Service, in such country was at the time of the First Commercial Sale
      thereof in such country covered by a Valid Claim, the term for which
      Valid Claim remains in effect and would be infringed, by the
      manufacture, use or sale of such Royalty Product, or the performance of
      such Royalty Service, in such country.
    

    
      “Section 338(h)(10) Elections” is defined in Section
      7.1(d)(viii)(A).
    

    
      “Securities Act” means the Securities Act of 1933,
      as amended.
    

    
      “Security Agreement” is defined in Section
      3.1(b).
    

    
      “Seller” is defined in the introductory paragraph.
    

    
      “Seller Applicable Law” is defined in Section
      4.5(a).
    

    
      
        

        

      

      
        
          - 14 -
        

        
          

        

      

      
        

        

      

    

    
      “Seller Disclosure Schedule” is defined in Article IV.
    

    
      “Seller Indemnified Parties” is defined in Section
      8.3(a).
    

    
      “Shares” means all of the issued and outstanding
      shares of the common stock of the Company.
    

    
      “Stock Purchase” is defined in Recital C.
    

    
      “Straddle Period” means any Tax period of the
      Company that begins on or before the Closing Date and ends after the
      Closing Date.
    

    
      “Sublessor” is defined in Section 7.1(j).
    

    
      “Subsidiary” shall mean, with respect to any Person,
      any corporation or other organization, whether incorporated or
      unincorporated, of which (a) at least a majority of the securities or
      other interests having by their terms ordinary voting power to elect a
      majority of the board of directors or others performing similar
      functions with respect to such corporation or other organization is
      directly or indirectly owned or controlled by such Person or by any one
      or more of its Subsidiaries, or by such Person and one or more of its
      Subsidiaries or (b) such Person or any other Subsidiary of such Person
      is a general partner (excluding any such partnership where such Person
      or any Subsidiary of such Person does not have a majority of the voting
      interest in such partnership).
    

    
      “Taxes” means any income, capital gain, gross
      receipts, license, payroll, employment, excise, severance, stamp,
      occupation, premium, windfall profit, customs, capital stock, franchise,
      employees’ income withholding, foreign or domestic withholding, social
      security, unemployment, disability, real property, personal property,
      sales, use, transfer, value added, alternative, add-on minimum or other
      tax, fee, assessment, levy, tariff, charge or duty of any kind
      whatsoever and any interest, penalty, fine, addition or additional
      amount thereon imposed, assessed or collected by any Governmental
      Authority.
    

    
      “Tax Return” means all returns, declarations,
      reports, claims for refunds, information returns or similar documents
      (including any related or supporting schedules or statements of
      information) filed or required to be filed in connection with the
      determination, assessment or collection of Taxes or the administration
      of any laws relating to any Taxes.
    

    
      “Third Party Claim” is defined in Section 8.4(b)(i).
    

    
      “To the Purchaser’s knowledge” or any phrase
      of similar import means the actual knowledge, after inquiry, of Cam
      Gallagher or Ed O’Sullivan.
    

    
      “To the Seller’s knowledge” or any phrase of
      similar import means the actual knowledge, after inquiry, of Charles L.
      Dimmler, III, John A. Herrmann III, Philip L. Rohrer, Jr., F. Dudley
      Staples, Jr. and Larry M. Tiffany.
    

    
      “Transaction Documents” means this Agreement, the
      Note and the Security Agreement.
    

    
      “Transfer Taxes” is defined in Section 7.1(d)(vi).
    

    
      “Treasury Regulations” means the income tax
      regulations (final, temporary and, as applicable, proposed) promulgated
      under the Code, as they may be in effect from time to time.
    

    
      “Valid Claim” means a claim of an issued and
      unexpired patent within the Company’s Registered Intellectual Property,
      which has not been held permanently revoked, unenforceable or invalid by
      a decision of a court or other governmental agency of competent
      jurisdiction, unappealable or unappealed within the time allowed for
      appeal, and which has not been admitted to be invalid or unenforceable
      through reissue or disclaimer or otherwise.
    

    
      “Underpayment Amount” is defined in Section
      3.3(b).
    

    
      “Working Balance” means the value of total current
      assets less any total current liabilities (including income
      tax-related liabilities) of the Business and less any cash and
      any inter-company payables between Company and Seller, in each case
      calculated in accordance with GAAP consistently applied.
    

    
      
        

        

      

      
        
          - 15 -
        

        
          

        

      

      
        

        

      

    

    
      “Working Balance Ceiling” is defined
      in Section 3.3(a).
    

    
      “Working Balance Floor” is defined in Section 3.3(a).
    

    
      
        

        

      

      
        
          - 16 -
        

        
          

        

      

      
        

        

      

    

    
      ARTICLE II  – PURCHASE AND SALE OF SHARES
    

    
      2.1  The Stock Purchase.
    

    
      Upon the terms and subject to the conditions set forth in this
      Agreement, at the Closing, the Seller shall sell, convey, assign,
      transfer and deliver to the Purchaser the Shares, free and clear of all
      Liens or other defects of title, and the Purchaser shall purchase,
      acquire and accept the Shares from the Seller.  
    

    
      2.2  Closing.
    

    
      Subject to the terms and conditions of this Agreement, the closing of
      the Stock Purchase (the “Closing”) shall be deemed
      effective as of 12:00 a.m. Eastern Daylight Time on September 19, 2008
      (the “Closing Date”).  At the Closing, which may be
      conducted telephonically and by electronic transfer of documents, the
      parties to this Agreement each shall deliver all documents, instruments,
      certificates and other items as may be required under this Agreement.  
    

    
      2.3  Books and Records.
    

    
      At the Closing, the Purchaser shall own all books and records of the
      Business.  As soon as reasonably practicable following the Closing, the
      Seller shall deliver the books and records of the Business to the
      Purchaser, subject to Section 7.1(g).
    

    
      ARTICLE III  – CONSIDERATION
    

    
      3.1  Consideration for Shares.
    

    
      The consideration for the Shares shall be the Purchase Price and the
      Royalty Consideration.  The Purchaser shall pay an aggregate purchase
      price (the “Purchase Price”) of $1,250,000 for the
      Shares, which shall be payable as follows (and later subject to
      adjustment pursuant to Section 3.3):
    

    
      (a)  $500,000 of the Purchase Price (the “Initial
      Payment”) shall be paid by wire transfer of immediately
      available funds to the Seller at Closing; and
    

    
       (b)  $375,000 of the Purchase Price shall be paid by wire transfer of
      immediately available funds to the Seller on or before December 31, 2009
      and $375,000 of the Purchase Price (collectively, the “Delayed
      Payment”) shall be paid by wire transfer of immediately
      available funds to the Seller on or before June 30, 2010, as evidenced
      by a secured promissory note (the “Note”) in the
      form attached as Exhibit A hereto and the Security Agreement (the
      “Security Agreement”) in the form attached as Exhibit
      B hereto.  The Delayed Payment is subject to acceleration pursuant
      to the terms of the Note.  
    

    
      Immediately prior to Closing, the Company shall distribute all of its
      cash, if any, to the Seller.
    

    
      At Closing, the Company shall have no Funded Indebtedness.
    

    
      3.2  Calculation of Final Working Balance.
    

    
      
        

        

      

      
        
          - 17 -
        

        
          

        

      

      
        

        

      

    

    
      On or before thirty (30) calendar days after the Closing Date, the
      Seller shall deliver to the Purchaser a statement, dated as of the
      Closing Date, in reasonable detail prepared in accordance with GAAP
      consistently applied showing the amounts of Working Balance as of the
      Closing Date (the “Proposed Final Working Balance Statement”).  Within
      forty-five (45) calendar days of the Purchaser’s receipt of such
      Proposed Final Working Balance Statement, the Purchaser may give written
      notice to the Seller that it disputes certain items contained in any of
      the Proposed Final Working Balance Statement (the “Dispute
      Notice”), which shall specify in reasonable detail the dollar
      amount of any objection and basis therefor; provided, however,
      that if the Purchaser does not deliver a Dispute Notice by such date,
      the Purchaser will be deemed to have accepted such Proposed Final
      Working Balance Statement and the Proposed Final Working Balance
      Statement shall be final and binding on both the Purchaser and the
      Seller.  Upon timely delivery of the Dispute Notice, the Purchaser and
      the Seller agree to confer in good faith with regard to the disputed
      items and an appropriate adjustment to the Proposed Final Working
      Balance Statement shall be made to the extent agreed upon by the
      Purchaser and the Seller.  If within twenty (20) Business Days after
      delivery of a Dispute Notice, the Purchaser and the Seller are unable to
      resolve the matter, either of them may within twenty (20) Business Days
      after the end of the previous twenty (20) Business Day period notify in
      writing the other party of its intention to submit the dispute to
      arbitration.  Within ten (10) Business Days after receipt of such
      notice, the Seller and the Purchaser shall in good faith jointly select
      an arbitrator with expertise in accounting and GAAP and experience
      resolving financial disputes (the “Arbitrator”),
      who shall adjudicate only those items still in dispute with respect to
      the Proposed Final Working Balance Statement.  The Purchaser and the
      Seller shall have the opportunity to provide written submissions
      regarding their positions on the disputed matters, which written
      submissions shall be provided to the Arbitrator, if at all, no later
      than fifteen (15) Business Days after the date of referral of the
      disputed matters to the Arbitrator.  The Arbitrator shall deliver a
      written report resolving only the disputed matters and setting forth the
      basis for such resolution within thirty (30) Business Days after the
      Purchaser and the Seller have submitted in writing (or have had the
      opportunity to submit in writing but have not submitted) their positions
      as to the disputed items.  The Arbitrator shall not value any item
      greater than the highest amount proposed by either party for such item
      or lower than the lowest amount proposed by either party for such
      item.  The determination of the Arbitrator with respect to the
      correctness of each matter in dispute shall be final and binding on the
      Purchaser and the Seller.  The fees, costs and expenses of the
      Arbitrator shall be evenly split between the Purchaser and the
      Seller.  The Working Balance agreed upon by the Seller and the Purchaser
      (or deemed accepted by the Purchaser) under this subsection, as
      adjusted, if necessary based on a decision by the Arbitrator hereunder,
      is referred to herein as the “Final Working Balance.”
    

    
      3.3  Adjusted Initial Payment.  
    

    
      (a)  If the Final Working Balance is less than -$12,500 (the “Working
      Balance Floor”), then the Initial Payment shall be decreased by
      the difference between the Final Working Balance and the Working Balance
      Floor.  If the Final Working Balance is greater than $12,500 (the “Working
      Balance Ceiling”), then the Initial Payment shall
      be increased by the difference between the Final Working Balance and the
      Working Balance Ceiling.  
    

    
      (b)  If the amount of the Initial Payment, as adjusted pursuant to Section 3.3(a)
      (the “Adjusted Initial Payment”), is greater than
      the Initial Payment paid by the Purchaser at the Closing (the “Underpayment
      Amount”), then the Purchaser shall pay or cause to be paid to
      the Seller the Underpayment Amount.  If the Adjusted Initial Payment is
      less than the Initial Payment paid by the Purchaser at the Closing (the “Overpayment
      Amount”), then the Seller shall pay to the Purchaser the
      Overpayment Amount.  Any payment due pursuant to this Section 3.3(b)
      shall be made by wire transfer of immediately available funds within ten
      (10) Business Days after the Final Working Balance becomes final and
      binding as provided above.
    

    
      
        

        

      

      
        
          - 18 -
        

        
          

        

      

      
        

        

      

    

    
      3.4  Delivery of Shares.
    

    
      At the Closing, the Seller shall deliver to the Purchaser one or more
      certificates representing the Shares, each such certificate to be duly
      and validly endorsed in favor of the Purchaser or accompanied by a
      separate stock power duly and validly executed by the Seller and
      otherwise sufficient to vest in the Purchaser legal and beneficial
      ownership of the Shares, free and clear of all Liens.  
    

    
      ARTICLE IV – REPRESENTATIONS AND WARRANTIES OF THE SELLER
    

    
      The Seller represents and warrants to the Purchaser that, except as set
      forth in the disclosure schedules delivered by the Seller to the
      Purchaser concurrently herewith (the “Seller Disclosure
      Schedule”), the statements contained in this Article IV
      are true and correct.  The Purchaser acknowledges and agrees that
      (a) inclusion of information in any section of the Seller Disclosure
      Schedule shall not be construed as an admission that such information is
      material to the Business or the results of operations or financial
      condition of the Company; and (b) if any section of the Seller
      Disclosure Schedule lists an item or information in such a way as to
      make its relevance reasonably apparent on its face to another section of
      the Seller Disclosure Schedule, the matter shall be deemed to have been
      disclosed in such other section of the Seller Disclosure Schedule,
      notwithstanding the omission of an appropriate cross-reference to such
      other section.
    

    
      4.1  Organization, Qualification and Corporate Power.
    

    
      Each of the Company and the Seller is duly organized, validly existing,
      and in good standing, as applicable, under the laws of its jurisdiction
      of organization, with full corporate power and authority to conduct its
      business as currently conducted and to own and use the properties owned
      and used by it.  The Company is duly qualified to do business and is in
      good standing, as applicable, in the states of Delaware and Maryland.
    

    
      4.2  Enforceability.
    

    
      All corporate action on the part of the Seller and its officers,
      directors and stockholders necessary for the authorization, execution,
      delivery and performance of this Agreement and the other Transaction
      Documents to which the Seller is or will be a party, the consummation of
      the Stock Purchase, and the performance of all of the Seller’s
      obligations under this Agreement and the other Transaction Documents to
      which the Seller is or will be a party has been taken or will be taken
      as of or prior to the Closing.  No additional corporate or stockholder
      authorization or consent is required in connection with the
      foregoing.  This Agreement has been, and each of the other Transaction
      Documents to which the Seller is a party at the Closing will have been,
      duly executed and delivered by the Seller, and this Agreement is, and
      each of the other Transaction Documents to which the Seller is or will
      be a party will be (assuming the due authorization, execution and
      delivery by the other parties hereto and thereto) at the Closing a
      legal, valid and binding obligation of the Seller, enforceable against
      the Seller in accordance with its terms, except to the extent that
      enforceability hereof may be limited by applicable bankruptcy,
      insolvency, reorganization or other similar laws affecting the
      enforcement of creditors’ rights generally and by the principles of
      equity regarding the availability of remedies.
    

    
      
        

        

      

      
        
          - 19 -
        

        
          

        

      

      
        

        

      

    

    
      4.3  Subsidiaries.
    

    
      The Company does not have any Subsidiaries, and the Company does not
      own, directly or indirectly, any capital stock or other ownership
      interests, or have any obligations to acquire any capital stock or other
      ownership interests or make any investment, in any corporation,
      partnership, joint venture or other Person.
    

    
      4.4  No Violations; Consents.
    

    
      (a)  The execution and delivery of this Agreement and the other
      Transaction Documents by the Seller do not, and the performance by the
      Seller of its obligations under this Agreement and the other Transaction
      Documents and the consummation of the transactions contemplated hereby
      will not: (i) conflict with or violate any provision of the Amended and
      Restated Certificate of Incorporation or Bylaws, as amended, of the
      Seller or any organizational document of the Company or (ii) conflict
      with or constitute a default (or an event that with notice or lapse of
      time or both would become a default) under, result in creation of any
      Lien (other than a Permitted Lien) upon any properties or assets of the
      Seller, the Company or the Business, or give to any Person any right of
      termination, amendment, acceleration or cancellation (with or without
      notice, lapse of time or both) of, any Contract to which the Seller, the
      Company or the Business is a party or by which any properties or assets
      of the Seller, the Company or the Business are bound, result in a
      violation of any law or any judgment, decree, order, regulation or rule
      of any court or other Governmental Authority applicable to the Seller,
      the Company or the Business, except in the case of (ii) as would not be
      material to the Company or the operation of the Business.
    

    
      (b)  The execution and delivery of this Agreement and the other
      Transaction Documents by the Seller does not, and the performance of
      this Agreement and the other Transaction Documents by the Seller of its
      obligations hereunder and thereunder and the consummation of the
      transactions contemplated thereby will not, require any consent,
      approval, authorization or permit of, or filing by the Seller or the
      Company with or notification by the Seller or the Company to, any
      Governmental Authority, except for notice filings that are not material
      to the Company or the Business.  Section 4.4(a) of
      the Seller Disclosure Schedule sets forth all necessary consents,
      waivers and approvals of parties to any Contracts as are required
      thereunder in connection with the Stock Purchase, or for any such
      Contract to remain in full force and effect without limitation,
      modification or alteration or the payment of any additional
      consideration after the Closing as a result of the Stock Purchase.  
    

    
      4.5  Permits; Compliance with Law.
    

    
      (a)  To the Seller’s knowledge, neither the Company nor the Business:
      (i) is or has been in conflict with, or in default or in violation of
      any decree, order or arbitration award; or (ii) is or has been in any
      material respect in conflict with, or in default or in violation of, any
      law, statute, rule or regulation of any Governmental Authority
      applicable to the Company or the Business or by which the Company or the
      Business is bound or affected (“Seller Applicable Law”).  The
      Company and the Business have not received written notice or
      communication from any Governmental Authority alleging noncompliance
      with any Seller Applicable Law.  There is no judgment, injunction, order
      or decree of a Governmental Authority binding upon the Company or the
      Business that materially prohibits or impairs the current operation of
      the Company and the Business, taken as a whole.  The Seller and the
      Company have not received written notice of, and the Seller has no
      knowledge of, any investigation of the Company or the Business by any
      Governmental Authority with respect to any alleged failure or compliance
      with any Seller Applicable Law.
    

    
      
        

        

      

      
        
          - 20 -
        

        
          

        

      

      
        

        

      

    

    
      (b)  To the Seller’s knowledge, the Company and the Business hold, to
      the extent legally required, all Permits from Governmental Authorities
      that are material and necessary to the operation of the Company and the
      Business up to and until the Closing Date, taken as a whole
      (collectively, “Company Permits”).  As of the date
      hereof, no suspension, revocation, cancellation or material modification
      of any of the Company Permits is pending or, to the knowledge of the
      Seller, threatened.  The Company and the Business are in compliance in
      all material respects with the terms of the Company Permits.  Section 4.5
      of the Seller Disclosure Schedule sets forth a list of the Company
      Permits.
    

    
      4.6  Capitalization.
    

    
      The authorized capital stock of the Company consists of 100,000 shares
      of common stock, $0.01 par value per share, of which 1,000 shares are
      outstanding and owned by the Seller, are duly authorized, validly
      issued, fully paid and non-assessable, are not subject to preemptive
      rights created by statute, the organizational document of the Company,
      or any agreement to which the Company is a party or by which it is
      bound, and are owned free of any Lien.  The Company has no other capital
      stock authorized, issued or outstanding.  There are no options, rights
      or agreements to which any of the Seller or the Company is a party or by
      which any of them may be bound obligating any of them (a) to issue,
      deliver or sell, or refrain from issuing, delivering or selling, any
      shares of capital stock of the Company, or to grant, extend or enter
      into any such option, right or agreement, (b) to repurchase, redeem or
      otherwise acquire, or to refrain from repurchasing, redeeming or
      otherwise acquiring, any shares of capital stock of the Company, or to
      grant, extend or enter into any such option, right or agreement or
      (c) to vote, or to refrain from voting, any shares of capital stock of
      the Company. All outstanding shares of the Company’s capital stock have
      been issued in compliance with Seller Applicable Law, including federal
      and state securities laws.  There are no declared or accrued but unpaid
      dividends with respect to any shares of the Company’s capital stock.  
    

    
      4.7  Financial Statements; No Undisclosed Liabilities; Internal
      Controls.
    

    
      (a)  The Financial Statements are set forth in Section 4.7
      of the Seller Disclosure Schedule.  The Financial Statements have been
      prepared in accordance with GAAP consistently applied during the periods
      covered thereby (unless as otherwise disclosed therein) and fairly
      present in all material respects the financial position and the results
      of operations of the Company as of the dates and during the periods
      indicated therein, except for (i) normal year-end adjustments that are
      not, individually or in the aggregate, material, and (ii) the omission
      of accompanying notes and schedules.  To the Seller’s knowledge, the
      Seller and the Company together have in their possession all books,
      records, documents and other information of the Company and Seller, in
      each case that is necessary to prepare audited financial statements for
      the periods covered by the Financial Statements in respect of the
      Business in accordance with GAAP and Regulation S-X promulgated under
      the Securities Act.
    

    
      
        

        

      

      
        
          - 21 -
        

        
          

        

      

      
        

        

      

    

    
             (b)  Except as reflected in the Financial Statements, the Company
      has no liabilities, obligations, indebtedness, expenses, claims,
      guarantees or endorsements of any type (whether accrued, absolute,
      contingent, matured, unmatured or otherwise) that are required by GAAP
      to be reflected on the balance sheet of the Company (collectively, “Liabilities”),
      except for Liabilities incurred since the Balance Sheet Date in the
      Ordinary Course of Business or that are not material.
    

    
             (c)  The Seller maintains internal controls over financial
      reporting (“Internal Controls”) that are designed to
      provide reasonable assurance, but not absolute assurance, that
      (i) records are maintained in reasonable detail, to accurately and
      fairly reflect the transactions and dispositions of the assets of the
      Seller and its consolidated Subsidiaries; (ii) transactions are recorded
      as necessary to permit preparation of financial statements of the Seller
      in accordance with GAAP, and that receipts and expenditures of the
      Seller and its consolidated Subsidiaries are being made only in
      accordance with authorizations of management and directors of the Seller
      and its consolidated Subsidiaries; and (iii) access to the Seller’s and
      its consolidated Subsidiaries’ assets is permitted only in accordance
      with management’s authorization.
    

    
             (d)  The Seller has disclosed,
      based on prior evaluations of such disclosure controls and procedures
      prior to the date hereof, to the Seller’s auditors and the audit
      committee of the Seller’s Board of Directors (i) any significant
      deficiencies and material weaknesses in the design or operation of
      Internal Controls over financial reporting that could adversely affect
      in any material respect the Seller’s and its consolidated Subsidiaries’
      ability to record, process, summarize and report financial information,
      and (ii) any fraud, whether or not material, known to the Seller that
      involves management or other employees who have a significant role in
      the Seller’s and its consolidated Subsidiaries’ Internal Controls over
      financial reporting.  The Seller has also disclosed to the Purchaser any
      such significant deficiencies, material weaknesses or fraud to the
      extent Seller believes such items could adversely affect either the
      continued operation of the Business in the Ordinary Course of Business.
    

    
             (e)  The Seller has identified all uncertain tax positions
      contained in all Tax Returns filed by the Seller (with respect to the
      Business) or the Company and has established adequate reserves and made
      any appropriate disclosures in the Financial Statements in accordance
      with the requirements of Financial Interpretation No. 48 of FASB
      Statement No. 109.
    

    
         4.8  Conduct of Business.
    

    
      Except as set forth on Section 4.8 of the Seller Disclosure
      Schedule or in connection with the transactions contemplated by this
      Agreement, since the Balance Sheet Date, neither the Company nor the
      Seller (in respect of the Business) has:
    

    
             (a)  taken any action or entered into or agreed to enter into any
      transaction, agreement or commitment other than in the Ordinary Course
      of Business;
    

    
      
        

        

      

      
        
          - 22 -
        

        
          

        

      

      
        

        

      

    

    
             (b)  had a Material Adverse Effect;
    

    
             (c)  increased, other than in the Ordinary Course of Business or
      as required by Seller Applicable Law, the compensation of any Business
      Employee;
    

    
             (d)  entered into, accelerated, terminated, modified or cancelled
      any employment or service contract with any Business Employee;
    

    
             (e)  sold, leased, transferred or otherwise disposed of any of
      its properties or assets (real, personal or mixed, tangible or
      intangible), except the sale of inventory in the Ordinary Course of
      Business or disposal of obsolete property;
    

    
             (f)  made any change in any method of accounting or accounting
      practice or internal control procedure;
    

    
             (g)  issued any capital stock, other securities or options or
      other rights to acquire capital stock or other securities, or declared,
      paid or set aside for payment any dividend or other distribution in
      respect of its capital stock, or redeemed, purchased or otherwise
      acquired, directly or indirectly, any shares of capital stock or other
      securities of the Company, or otherwise permitted the withdrawal by any
      of the holders of capital stock or equity interests of the Company of
      any cash or other assets (real, personal or mixed, tangible or
      intangible), in compensation, indebtedness or otherwise, other than
      payments of compensation in the Ordinary Course of Business;
    

    
             (h)  experienced any destruction of, damage to, or loss of any
      material tangible assets of the Company or the Business (whether or not
      covered by insurance);
    

    
             (i)  been involved in any employment dispute, including claims or
      matters raised by any individual or Governmental Authority, wrongful
      discharge or any other unlawful employment practice or action with
      respect to the Company or the Business;
    

    
             (j)  adopted or changed any Tax accounting method or material Tax
      election, entered into any closing agreement in respect of Taxes,
      compromised or settled any Tax claim, or extended or waived the
      limitation period applicable to any Tax claim or assessment;
    

    
             (k)  loaned or advanced (other than advance or reimbursement of
      expenses in the Ordinary Course of Business) any amount to, or sold,
      transferred or leased any properties or assets to, or entered into any
      agreement or arrangement with, any Business Employee;
    

    
             (l)  loaned money to any Person (except for advances or
      reimbursements to employees for expenses in the Ordinary Course of
      Business), or purchased any debt securities of any Person;
    

    
             (m)  (i) sold, leased, licensed or transferred any Company
      Intellectual Property or executed, modified or amended any agreement
      with respect to Company Intellectual Property with any Person or with
      respect to the Intellectual Property of any Person, (ii) purchased or
      licensed any Intellectual Property or executed, modified or amended any
      agreement with respect to the Intellectual Property of any Person, or
      (iii) entered into any agreement or modification or amendment of an
      existing agreement with respect to the development of any Intellectual
      Property with another Person;
    

    
      
        

        

      

      
        
          - 23 -
        

        
          

        

      

      
        

        

      

    

    
             (n)  acquired, or entered into any agreement to acquire, by
      merging or consolidating with, or by purchasing any assets or equity
      securities of, or by any other manner, any business or corporation,
      partnership, association or other business organization or division
      thereof, or other acquisition of any assets (outside the Ordinary Course
      of Business) or any equity securities that are material individually or
      in the aggregate to the Company or the Business;
    

    
             (o)  amended or otherwise changed its certificate of
      incorporation or bylaws (or comparable governing documents); or
    

    
             (p)  agreed, whether in writing or otherwise, to take any action
      described in this Section 4.8.
    

    
         4.9  Tangible Assets; Sufficiency of Assets.
    

    
             (a)  To the Seller’s knowledge, the Company has good title to, or
      a valid lease, license or right to use, all tangible assets and
      properties used in the conduct of the Business as it is currently
      conducted, free of any Liens, other than Permitted Liens.
    

    
             (b)  To the Seller’s knowledge, the Company’s tangible assets
      described in paragraph (a) above, together with the Intellectual
      Property owned by the Company or for which it has a valid right to use
      immediately following the Closing, constitute all the assets necessary
      for the operation of the Business as currently conducted and shall
      constitute all of the assets and properties necessary for the Company to
      continue to operate and conduct the Business immediately following the
      Closing in substantially the same manner as conducted by the Seller and
      the Company immediately prior to the Closing.
    

    
        4.10  Real Property.
    

    
             (a)  The Company has no Owned Real Property and the Company has
      never owned any Owned Real Property.
    

    
             (b)  The Company has leased no Leased Real Property and the
      Company has never leased any Leased Real Property.
    

    
             (c)  Section
      4.10(c) of the Seller Disclosure Schedule describes the office space
      utilized by the Company (the “Company Office Space”).  The
      Company Office Space constitutes all of the real property occupied or
      used by the Company, with the exception of the home offices of the
      Business Employees, and is sufficient for the conduct of the Business as
      it is currently conducted.
    

    
             (d)  The Company Office Space constitutes all of the real
      property occupied or used by the Company in connection with the Business.
    

    
      
        

        

      

      
        
          - 24 -
        

        
          

        

      

      
        

        

      

    

    
       4.11  Intellectual Property.
    

    
             (a)  Section 4.11(a)
      of the Seller Disclosure Schedule sets forth true, complete and correct
      lists of the following Intellectual Property, both U.S. and foreign,
      that are owned or claimed by the Company or the Business as of the date
      of this Agreement along with the jurisdiction in which each such item of
      Intellectual Property has been registered or filed and the applicable
      registration, application or serial number or similar identifier:
    

    
                 (i)  all patents and pending patent applications, including
      any and all extensions, continuations, continuations-in-part, divisions,
      reissues, reexaminations, substitutes, renewals, and foreign
      counterparts thereof;
    

    
                (ii)  all trademark registrations and pending trademark
      registration applications;
    

    
               (iii)  all copyright registrations and pending copyright
      registration applications; and
    

    
                (iv)  all domain name registrations and pending domain name
      registrations.
    

    
      For purposes of this Agreement, the “Company’s Registered
      Intellectual Property” shall mean the Intellectual Property set
      forth in Section 4.11(a) of the Seller Disclosure Schedule.
    

    
             (b)  All of the Company’s Registered Intellectual Property is
      owned exclusively by the Company.
    

    
             (c)  Except as set forth on Section
      4.11(c) of the Seller Disclosure Schedule, all of the Company’s
      Registered Intellectual Property is subsisting, and, to the Seller’s
      knowledge, valid and in full force and effect, and has not expired or
      been cancelled or abandoned.  All necessary documents and certificates
      in connection with such Company’s Registered Intellectual Property have
      been filed with the relevant patent, copyright, trademark or other
      authorities in the United States or foreign jurisdictions, as the case
      may be, for the purposes of avoiding abandonment, prosecuting and
      maintaining of such Company’s Registered Intellectual Property.
    

    
             (d)  Except for actions of the relevant jurisdiction’s patent and
      trademark office or other government intellectual property office (“Office
      Actions”), the Company has not received written notice of any
      pending or threatened Action before any Governmental Authority
      challenging the use, ownership, validity, enforceability or
      registerability of any of the Company Intellectual Property (as defined
      below).  Rejections of pending applications before a national patent,
      trademark or intellectual property office shall not constitute such
      written notice.  Except for Office Actions, neither the Company nor the
      Seller is a party to any settlements, covenants not to sue, consents,
      decrees, stipulations, judgments or orders resulting from Actions which
      permit third parties to use any of the Company’s Registered Intellectual
      Property.  Section 4.11(d) of the Seller
      Disclosure Schedule lists all Office Actions with respect to pending
      applications for the Company’s Registered Intellectual Property that may
      affect the validity, enforceability or registerability of such
      Registered Intellectual Property, and all such Office Actions have been
      made available to the Purchaser.
    

    
      
        

        

      

      
        
          - 25 -
        

        
          

        

      

      
        

        

      

    

    
             (e)  To the Seller’s knowledge, the Company owns or has valid
      rights to use all the Company Intellectual Property used in the Ordinary
      Course of Business, without infringing the Intellectual Property of any
      Person.  Without limiting the generality of the foregoing, to the
      Seller’s knowledge, the Company has the right to use all data, customer
      lists, log files, hardware designs, programming processes, software and
      other information used by the Company in the conduct of the Business as
      currently conducted, and has not been provided written notice that any
      of the foregoing that is provided to the Company by third parties will
      not continue to be provided to the Company on the same or similar terms
      and conditions as currently exist.  The Company’s ownership of all
      Company Intellectual Property is free and clear of any Lien; provided
      that the representation and warranty in this sentence shall not be
      deemed or construed as a representation or warranty, express or implied,
      regarding non-infringement, misappropriation or violation of any
      Intellectual Property of any Person (which is addressed solely in the
      first two sentences of this Section 4.11(e)).  To the
      Seller’s knowledge, the Company’s inbound license rights under the
      Intellectual Property in which the Company has any inbound license
      rights are subject to no restrictions except as set forth in the
      relevant inbound licenses or Seller Applicable Law.  Without limiting
      the foregoing, in respect of the Business of the Company, on the one
      hand, and the other business of the Seller and its Affiliates, on the
      other hand, except as set for in Section 4.11(d) of the Seller
      Disclosure Schedule, the Company exclusively owns all Intellectual
      Property primarily related to the Business, including (i) all patents
      and patent applications (x) that claim inventions or processes that
      primarily relate to, or that are primarily in the field of, the
      Business, (y) for which the inventors were primarily employed by or
      primarily engaged as contractors for the Company, or (z) the costs for
      which were attributed to or considered expenses of the Business, and
      (ii) all rights to enforce and to past and future damages for the
      infringement of any such Intellectual Property, and all goodwill of the
      Business associated with any trademark rights included in such
      Intellectual Property.
    

    
             (f)  To the Seller’s knowledge, the conduct of the Business as it
      has been conducted and is currently conducted has not infringed upon or
      misappropriated and does not infringe upon or misappropriate any
      Intellectual Property or other proprietary right owned by any Person,
      violate any right to privacy or publicity of any person, or constitute
      unfair competition or unfair trade practices under the laws of any
      jurisdiction where the Business is currently conducted.  As
      of the date of this Agreement, the Seller has not received written
      notice of any pending or threatened Actions against the Company alleging
      that such operation of the Business or any of its acts, products,
      services, technology or Intellectual Property infringes, misappropriates
      or otherwise violates the Intellectual Property of any Person, and
      neither the Company nor the Seller has received any written notice of
      any claims alleging that the Company or the Business infringes,
      misappropriates or otherwise violates the Intellectual Property of any
      Person (nor does the Seller have knowledge of any reasonable basis
      therefor).
    

    
             (g)  To the Seller’s knowledge, no third party is
      misappropriating, infringing, diluting (with respect to trademarks) or
      violating any Intellectual Property owned by the Company (collectively,
      and including the Company’s Registered Intellectual Property, the “Company
      Intellectual Property”), and no Intellectual Property or other
      proprietary right, misappropriation, infringement, trademark dilution or
      violation Actions have been brought against any third party by the
      Company.  The Company has not granted any exclusive license of or
      exclusive right to use, or authorized the retention of any exclusive
      rights to use or joint ownership of, any Company Intellectual Property.
    

    
      
        

        

      

      
        
          - 26 -
        

        
          

        

      

      
        

        

      

    

    
             (h)  Except for Office Actions pertaining to Company’s Registered
      Intellectual Property, the Company is not party to any settlement,
      covenant not to sue, consent, decree, stipulation, judgment, or order
      resulting from any Action which (i) restricts the Company’s rights to
      use any Intellectual Property, (ii) restricts the Company in order to
      accommodate a third party’s Intellectual Property rights or
      (iii) requires any future payment by the Company.  Except for
      restrictions set forth in inbound licenses of Intellectual Property, the
      Company is not subject to any covenant not to compete or contract,
      agreement or other arrangement limiting its ability to transact business
      in any market, field or geographical area or with any Person or
      prohibiting or impairing any acquisition of property (tangible or
      intangible by the Company).  The Company is not subject to any contract,
      agreement or other arrangement that:  (x) restricts the use, transfer,
      delivery or licensing of Company Intellectual Property or (y) grants to
      the Company any inbound license rights under any Person’s Intellectual
      Property rights that contains restrictions on use that are inconsistent
      with the Company’s business as currently conducted.
    

    
             (i)  All Business Employees, current and former employees,
      consultants and contractors of the Company who contribute or have
      contributed to the creation or development of any of the Company
      Intellectual Property have executed written instruments with the Company
      that assign all rights, title and interest in and to any such
      contributions to the Company substantially in the Company’s or Seller’s
      standard forms which have been made available to the Purchaser.  To the
      Seller’s knowledge, no current or former employee, officer, director,
      stockholder, consultant or independent contractor has any right, claim
      or interest in or with respect to any such contributions, any Company
      Intellectual Property or any Intellectual Property purported to be
      Company Intellectual Property.  To the Seller’s knowledge, other than
      under an appropriate confidentiality or nondisclosure agreement or
      contractual provision relating to confidentiality and nondisclosure,
      there has been no disclosure to any third party of material confidential
      or proprietary information or trade secrets of the Company.  To the
      Seller’s knowledge, without limiting the foregoing, neither the Company
      nor any Person acting on the Company’s behalf has disclosed, delivered
      or licensed to any Person, agreed to disclose, deliver or license to any
      Person, or permitted the disclosure or delivery to any escrow agent or
      other Person of any source code or related proprietary or confidential
      information or algorithms owned by the Company or used in its business (“Company
      Confidential Information”).  To the Seller’s knowledge, no event
      has occurred, and no circumstance or condition exists, that (with or
      without notice or lapse of time or both) will, or would reasonably be
      expected to, result in the disclosure or delivery by or on behalf of the
      Company of any Company Confidential Information.  
    

    
             (j)  Except for implied licenses attendant to the sale of
      non-software products, agreements relating solely to nondisclosure of
      confidential information and licenses granted to end-user customers in
      the Ordinary Course of Business, Section 4.11(j)(i) of the
      Seller Disclosure Schedule lists all contracts, licenses and agreements
      between the Company, on the one hand, and any other Person, on the other
      hand, with respect to any Company Intellectual Property, including any
      agreements with respect to the licensing and distribution thereof.  Section 4.11(j)(ii)
      of the Seller Disclosure Schedule lists all contracts, licenses and
      agreements between the Company, on the one hand, and any other Person,
      on the other hand, with respect to any Intellectual Property of any
      other Person, including any agreements with respect to the licensing and
      distribution thereof, except for generally available commercial binary
      code-only software product supplied under end-user licenses and implied
      licenses attendant to the purchase of non-software products.
    

    
      
        

        

      

      
        
          - 27 -
        

        
          

        

      

      
        

        

      

    

    
             (k)  Section
      4.11(k) of the Seller Disclosure Schedule sets forth any Open Source
      Code that is contained in any current or past product or service offered
      by the Company, if any, or that has otherwise been used in the Ordinary
      Course of Business.  
    

    
             (l)  To the Seller’s knowledge, the Company has no obligation to
      pay any third party any future royalties or other fees for the continued
      use of Intellectual Property and will not have any obligation to pay
      such royalties or other fees arising from the consummation of the
      transactions contemplated by this Agreement.  The Company has not
      licensed any of its Intellectual Property to any Person on an exclusive
      basis.
    

    
             (m)  To the Seller’s knowledge, the Company is not in violation
      of any contract, agreement, license or other instrument to which it is a
      party or otherwise bound relating to Intellectual Property that is
      material to the Company in the Ordinary Course of Business.  The
      consummation by the Seller and the Company of the transactions
      contemplated hereby, including the Stock Purchase, will not result in
      any violation, loss or impairment of ownership by the Company of, or
      impair or restrict the right of any of the Company to use, any
      Intellectual Property that is material to the Company in the Ordinary
      Course of Business, and will not require the consent of any Governmental
      Authority or third party with respect to any such Intellectual
      Property.  Neither this Agreement nor the transactions contemplated by
      this Agreement will, pursuant to any Contract to which the Seller or its
      Affiliate, including the Company, is a party, result in the Purchaser or
      the Company or any Subsidiaries of the Purchaser:  (i) granting to any
      third party any right to or with respect to any Intellectual Property
      owned by, or licensed to the Company, (ii) being bound by or subject to,
      any exclusivity obligations, non-compete or other restriction on the
      operation or scope of the Company, except as may be imposed by Seller
      Applicable Law, or (iii) being obligated to pay any royalties or other
      material amounts to any third party in excess of those payable by any of
      them, respectively, in the absence of this Agreement or the transactions
      contemplated hereby.
    

    
             (n)  Except for inbound licenses for generally available
      commercial binary code-only software product supplied under end user
      licenses, implied licenses attendant to the sale or purchase of
      non-software products, and licenses to end-user customers in the
      Ordinary Course of Business, the contracts, licenses and agreements
      listed in Section 4.11(n) of the Seller Disclosure Schedule
      constitute all material contracts, licenses and agreements currently in
      effect to which the Company is a party with respect to any Intellectual
      Property, including all licenses currently in effect of Intellectual
      Property granted to or by the Company and all assignments of material
      Intellectual Property (relating to Intellectual Property that is
      material to the Company in the Ordinary Course of Business as currently
      conducted) to or by the Company, except for assignments by employees
      pursuant to invention or copyright assignment agreements.
    

    
      
        

        

      

      
        
          - 28 -
        

        
          

        

      

      
        

        

      

    

    
             (o)  Section
      4.11(o) of the Seller Disclosure Schedule identifies each Material
      Contract involving government funding or the sue of a facility of a
      university, college, other educational institution or research center
      was used in the development of any Company Intellectual Property.  Other
      than as described in Section 4.11(o) of the Seller Disclosure
      Schedule, (i) the Seller has no knowledge of any Governmental Authority,
      university, college or other educational institution or research center
      having been granted any rights under, or to the Seller’s knowledge, nor
      any claim or right in or to, any Company Intellectual Property (or any
      Intellectual Property purported to be Company Intellectual Property) and
      (ii) the Company has not sponsored any research and development with any
      Governmental Authority, university, college or other educational
      institution or research center except pursuant to an agreement whereby
      the Company acquired exclusive rights to the results of such research
      and development for the term of any underlying Intellectual Property
      rights.
    

    
             (p)  To the Seller’s knowledge, the Company has complied with all
      laws regarding the protection of Clinical Subject Protected Health
      Information.  The transactions contemplated by the Agreement will not
      violate any laws or agreements between the Company or the Seller and its
      patients or clinical subjects relating to Clinical Subject Protected
      Health Information.
    

    
             (q)  The Company is not and was never a member or promoter of, a
      contributor to, or a participant in, any industry standards body or
      similar organization that could require or obligate the Company to grant
      or offer to any other Person any license or right to any Intellectual
      Property.
    

    
             (r)  Immediately following the Closing, the Company will not
      infringe upon, or require any license or consent to use, any
      Intellectual Property of the Seller in the Ordinary Course of Business.
    

    
        4.12  Material Contracts.
    

    
             (a)  Set forth on Section 4.12(a)
      of the Seller Disclosure Schedule are all of the Contracts (with
      remaining rights or obligations) either entered into by the Company or
      entered into by the Seller primarily for the benefit of the Business
      (collectively, together with the Contracts set forth in Section 4.11(j)(i)
      and (ii) of the Seller Disclosure Schedule, the “Material
      Contracts”).
    

    
             (b)  The Seller has made available to the Purchaser true and
      complete copies of all of the Material Contracts.  With respect to the
      Material Contracts, (i) each Material Contract is valid, binding and
      enforceable in accordance with its terms; (ii) neither the Company nor
      the Seller is in material default under or in material violation of any
      provision of any of the Material Contracts; (iii) neither the Company
      nor the Seller has received notice of alleged nonperformance or other
      noncompliance with respect to its obligations under any of the Material
      Contracts, which alleged nonperformance or other noncompliance is
      currently unresolved, nor any notice that is currently unresolved that
      any of the Material Contracts may be totally or partially terminated or
      suspended by any other party thereto; and (iv) to the Seller’s
      knowledge, no other party to any Material Contract is in breach or
      noncompliance with its obligations under such Material Contract.  To the
      Seller’s knowledge, there are no pending renegotiations of any of the
      Material Contracts and all new Contracts which are being actively
      negotiated and which would be required to be listed on Section 4.12(a)
      of the Seller Disclosure Schedule are so listed and indicated as
      “pending.”
    

    
      
        

        

      

      
        
          - 29 -
        

        
          

        

      

      
        

        

      

    

    
        4.13  Intentionally Omitted.
    

    
        4.14  Intentionally Omitted.
    

    
        4.15  Tax Matters.
    

    
             (a)  All Tax Returns required to be filed in respect of the
      Business or the Company have been duly and timely filed in all required
      jurisdictions (taking into account all applicable extensions), and all
      such Tax Returns are true, correct and complete in all material
      respects.  All Taxes and other charges for which the Company is or may
      be liable (whether or not shown on or required to be shown on any Tax
      Return) have been duly and timely paid.  As of the Balance Sheet Date,
      there were no Liabilities for unpaid Taxes, whether asserted or
      unasserted, contingent or otherwise that had not been reserved on the
      Current Balance Sheet.  There are no Liens for Taxes on assets of the
      Company or the Business except for Permitted Liens.  The Company has not
      incurred any Liabilities for Taxes, other than in the ordinary course of
      business since the Balance Sheet Date.
    

    
             (b)  No audit or other proceeding by any Governmental Authority
      is pending or, to the Seller’s knowledge, threatened with respect to any
      Taxes due from the Company or related to the Business or any Tax Return
      filed or required to be filed in respect of the Business or the
      Company.  No assessment or deficiency for any Tax has been proposed or,
      to the Seller’s knowledge, threatened in respect of the Business or the
      Company.  There are no unexpired waivers of any statute of limitations
      with respect to any Taxes for which the Company may be liable.  Neither
      the Company nor the Seller on Company’s behalf is the beneficiary of any
      extension of time within which to file any Tax Return.
    

    
             (c)  None of the Company, the Seller or any of the Seller’s ERISA
      Affiliates has made any payments to any Business Employee or is a party
      to a contract, agreement or arrangement with any Business Employee to
      make payments individually or considered collectively with any
      other such agreements, plans, arrangements or other contracts, that
      will, or could reasonably be expected to, be characterized as a
      “parachute payment” within the meaning of Section 280G(b)(1) of the
      Code.  There is no agreement, plan, arrangement or other contract by
      which the Company, the Seller or any of its ERISA Affiliates is bound to
      compensate any Business Employee for excise taxes paid pursuant to
      Section 4999 of the Code.  
    

    
             (d)  Each “nonqualified
      deferred compensation plan” (as that term is defined in
      Section 409A(d)(1) of the Code), if any, sponsored or maintained by the
      Company, Seller or any ERISA Affiliate on or after January 1, 2005 in
      which a Business Employee participates has been operated since
      January 1, 2005 in good faith compliance with Section 409A of the Code
      and the Treasury Regulations thereunder, to the extent applicable.  No
      deferred compensation plan sponsored or maintained by the Company, the
      Seller or any ERISA Affiliate in which a Business Employee participates
      and existing prior to January 1, 2005, which would otherwise be subject
      to Section 409A, has been “materially modified” at any time after
      October 3, 2004.
    

    
      
        

        

      

      
        
          - 30 -
        

        
          

        

      

      
        

        

      

    

    
             (e)  The Company has not been a United States real property
      holding corporation within the meaning of Section 897(c)(2) of the Code
      during the applicable period specified in Section 897(c)(1)(A)(ii) of
      the Code.
    

    
             (f)  The Company is not a party to any Tax allocation, sharing or
      similar agreement.  The Company (i) has never been a member of an
      affiliated group filing a consolidated income Tax Return under
      Section 1501 of the Code or any similar provision of state, local,
      foreign or other law (other than a group the common parent of which was
      the Seller) and (ii) has no liability for Taxes of any Person (other
      than its own) under Treasury Regulations Section 1.1502-6 (or any
      similar provision of state, local, foreign or other law), as a
      transferee or successor, by contract, by operation of law, or otherwise.
    

    
             (g)  All Taxes in respect of the Business and the Company
      required to have been withheld and paid in connection with any amounts
      paid or owing to any independent contractor, creditor, stockholder or
      other third party have been withheld and paid.  
    

    
             (h)  Neither the Seller nor the Company has engaged in a
      “reportable transaction,” within the meaning of Treasury Regulations
      Section 1.6011-4(b).
    

    
             (i)  No written claim has ever been made by a tax authority in a
      jurisdiction where the Company does not file Tax Returns that the
      Company is or may be subject to taxation by that jurisdiction.
    

    
             (j)  The Company is in compliance in all material respects with
      all applicable transfer pricing laws and regulations, including the
      maintenance of contemporaneous documentation substantiating the transfer
      pricing practices and methodology of the Company.
    

    
             (k)  The Company has not distributed stock of another Person, or
      has had its stock distributed by another Person, in a transaction that
      was purported or intended to be governed in whole or in part by
      Section 355 or 361 of the Code.
    

    
             (l)  The Company will not be required to include any item of
      income in, or exclude any item of deduction from, taxable income for any
      taxable period (or portion thereof) ending after the Closing Date as a
      result of any:
    

    
      
        

        

      

      
        
          - 31 -
        

        
          

        

      

      
        

        

      

    

    
                 (i)  change in method of accounting made prior to the Closing
      for a taxable period ending on or prior to the Closing Date pursuant to
      Section 481 of the Code (or any similar provision of state, local,
      foreign or other law);
    

    
                (ii)  “closing agreement” as described in Section 7121 of the
      Code (or any similar provision of state, local, foreign or other law)
      executed on or prior to the Closing;
    

    
               (iii)  intercompany transaction or excess loss account
      described in Treasury Regulations under Section 1502 of the Code (or any
      similar provision of state, local, foreign or other law) in connection
      with a transaction consummated prior to the Closing;
    

    
                (iv)  installment sale or open transaction disposition made on
      or prior to the Closing; or
    

    
                 (v)  prepaid amount received on or prior to the Closing.
    

    
             (m)  The purchase and sale contemplated by this Agreement are not
      part of a transaction identified in IRS Notice 2001-16, 2001-1 C.B. 730,
      as modified and supplemented by IRS Notice 2008-20, 2008-6 I.R.B. 406.
    

    
        4.16  Legal Proceedings.
    

    
      There is no action, suit, claim or proceeding (collectively, “Actions”)
      of any nature pending, or to the Seller’s knowledge, threatened, against
      the Company, their respective properties (tangible or intangible) or any
      of the Company’s officers or directors (in their capacities as such).
    

    
        4.17  Employee Benefits.
    

    
             (a)  There are no Benefit Plans sponsored by the Company; and,
      immediately after Closing, there will be (i) no Benefit Plans sponsored
      by the Seller or any of its ERISA Affiliates (other than the Company)
      with respect to which the Company will have any material liability or
      obligation on or after the Closing and (ii) no Benefit Plans previously
      (but no longer) sponsored by the Company for which the Company will have
      any material liability or obligation on or after the Closing.  
    

    
             (b)  From and after the Closing, except as required by COBRA or
      Seller Applicable Law, any Benefit Plans sponsored by the Seller and any
      of its ERISA Affiliates will no longer be available to any Business
      Employee and, except as required by COBRA or Seller Applicable Law, upon
      the Closing, all Business Employees shall cease to be eligible to
      participate in the Benefit Plans of Seller and, as applicable, its ERISA
      Affiliates.
    

    
             (c)  Neither Seller nor any of its ERISA Affiliates has ever
      maintained, established, sponsored, participated in, contributed to (or
      been obligated to contribute to) any (A) employee pension benefit plan
      (as defined in Section 3(2) of ERISA) which is subject to Part 3 of
      Subtitle B of Title I of ERISA, Title IV of ERISA or Section 412 of the
      Code, (B) multiple employer plan (within the meaning of Section 4063 or
      4064 of ERISA or Section 413 of the Code) which is subject to ERISA, or
      (C) any multiemployer plan (as defined in Section 3(37) of ERISA) which
      is subject to ERISA.
    

    
      
        

        

      

      
        
          - 32 -
        

        
          

        

      

      
        

        

      

    

    
             (d)  Section 4.17(d)
      of the Disclosure Schedule contains a complete list of all material
      Benefit Plans sponsored by the Seller and its ERISA Affiliates in which
      Business Employees are eligible to participate.  Seller
      and, as applicable, its ERISA Affiliates, are in material compliance
      with the terms of each such Benefit Plan and all applicable laws for
      each such Benefit Plan including ERISA and the Code.
    

    
             (e)  No Benefit Plan (provides, or has any liability to provide,
      life insurance, medical or other welfare benefits within the meaning of
      Section 3(1) of ERISA) to any current or former Business Employee upon
      his or her retirement or termination of employment for any reason,
      except as may be required by Seller Applicable Law, including COBRA, and
      neither Seller nor any of its ERISA Affiliates has ever represented,
      promised or contracted (whether in oral or written form) to any Business
      Employee (either individually or as a group) that any such individual
      would be provided with life insurance, medical or other employee welfare
      benefits upon their retirement or termination of employment, except to
      the extent required by Seller Applicable Law.
    

    
        4.18  Employees.
    

    
             (a)  Section 4.18(a)(i)
      of the Disclosure Schedule lists as of the date hereof the name, title,
      location, annual salary, commission, and bonus of each Person who is
      employed by the Company or the Seller and devotes at least forty percent
      (40%) of their time on an annualized basis working for the Company
      and/or the Business.  Section 4.18(a)(ii) of the
      Seller Disclosure Schedule lists as of the date hereof all Persons that
      devote time to the Business pursuant to a service, contractor,
      consulting or advisory relationship with the Seller or the Company with
      their respective start date and compensation terms.
    

    
             (b)  The termination of the employment of all of the employees
      listed on Section 4.18(a)(i) of the Seller Disclosure Schedule
      would not result in any liability to the Company.  Section
      4.18(b) of the Seller Disclosure Schedule lists all liabilities of
      the Seller to any employee, that result from the termination by the
      Seller of such employee’s employment, a change of control of the
      Company, or a combination thereof.  
    

    
             (c)  The Company is in compliance in all material respects with
      Seller Applicable Law respecting employment, employment practices, terms
      and conditions of employment and wages and hours, worker classification,
      tax withholding, prohibited discrimination, equal employment, fair
      employment practices, immigration status, employee safety and health,
      wages, compensation, and hours of work, and in each case, with respect
      to all employees, (i) has withheld and reported all amounts required by
      law or by agreement to be withheld and reported with respect to wages,
      salaries and other payments to all workers, (ii) is not liable for any
      arrears of wages, severance pay or any taxes or penalties or any penalty
      for failure to comply with any of the foregoing and (iii) is not liable
      for payment to any trust or other fund governed by or maintained by or
      on behalf of any Governmental Authority, with respect to unemployment
      compensation benefits, social security or other benefits or obligations
      for employees (other than routine payments to be made in the Ordinary
      Course of Business).  The Company has no material liability with respect
      to the misclassification of: (a) any Person as an independent contractor
      rather than as an employee, (b) any employee leased from another
      company, or (c) any employee currently or formerly classified as exempt
      from overtime wages.
    

    
      
        

        

      

      
        
          - 33 -
        

        
          

        

      

      
        

        

      

    

    
             (d)  There are no pending or, to the Seller’s knowledge,
      threatened Actions or administrative claims against the Seller, Company,
      or any Business Employee (in their capacity as such) relating to any
      Business Employee or Benefits Plan, including, but not limited to claims
      arising from the following: (u) with respect to harassment, whether
      sexual or otherwise; (v) with respect to negligence or other wrongdoing
      on the part of the Company or the Seller, whether occurring on or off
      the Company or the Seller’s property; (w) under any workers’
      compensation policy or long-term disability policy; (x) with respect to
      a violation of any occupational safety or health standards; (y) with
      respect to a charge of discrimination in employment or employment
      practices, for any reason, including age, gender, race, religion or
      other legally protected category; or (z) with respect to payment of
      wages, compensation or benefits.  
    

    
             (e)  To the knowledge of Seller, no Business Employee is in
      violation of any term of any patent disclosure agreement,
      non-competition agreement, or any restrictive covenant to a former
      employer relating to the right of any such employee to be employed by
      the Seller or Company because of the nature of the Business conducted by
      the Seller or Company or to the use of trade secrets or proprietary
      information of others.  
    

    
        4.19  Environmental Matters.
    

    
             (a)  To the Seller’s knowledge, the Company possesses all
      material Environmental Permits that are required for the operation of
      the Business as currently conducted by the Company, and the Company has
      complied in all material respects with such Environmental Permits.  To
      the Seller’s knowledge, complete copies of such Environmental Permits,
      if any, have been delivered or made available to the Purchaser.  To the
      Seller’s knowledge, all of the Environmental Permits are in full force
      and effect, and there is no actual or threatened proceeding to revoke
      any such Environmental Permit.
    

    
             (b)  To the Seller’s knowledge, the Company and the Business have
      been and are in material compliance with all applicable Environmental
      Laws.
    

    
             (c)  To the Seller’s knowledge, the Company has not received any
      written notice from any Governmental Authority regarding any actual or
      alleged material violation of Environmental Laws or Environmental
      Permits, including any investigatory, remedial, or corrective
      obligations relating to the Company or its facilities arising under
      Environmental Laws.
    

    
             (d)  Except in compliance with Environmental Laws and in a manner
      that would not reasonably be expected to subject the Company to material
      liability, no asbestos-containing materials, polychlorinated biphenyls,
      underground storage tank, or landfill, impoundment or other disposal
      area containing Hazardous Materials, is present on the Company Office
      Space or were present on any other real property at the time it ceased
      to be operated by the Company.
    

    
             (e)  To the Seller’s knowledge, all waste materials generated by
      the Company have been properly stored, transported, treated and disposed
      of in accordance with all applicable Environmental Laws.  To the
      Seller’s knowledge, neither the Company nor the Seller (with respect to
      the Business) has entered into any agreement that may require it to
      guarantee, reimburse, pledge, defend, hold harmless or indemnify any
      other party with respect to liabilities arising out of Environmental
      Laws of the Company or the Business.
    

    
      
        

        

      

      
        
          - 34 -
        

        
          

        

      

      
        

        

      

    

    
             (f)  There are no assessments or investigations in the possession
      of the Company or the Seller concerning possible non-compliance by the
      Company or the Seller with Environmental Laws or the presence of
      Hazardous Materials on the Company Office Space.
    

    
        4.20  Related Party Transactions.
    

    
      The Company is not party to any Contract with the Seller or any of the
      Company’s or Seller’s current or former directors or officers, the
      Seller’s Affiliates or, to the Seller’s knowledge, any immediate family
      member of any of such Persons, or any trust, partnership or corporation
      in which any of such Persons has or has had an interest (the “Related
      Parties”) other than normal employment arrangements.  No Related
      Party (other than the Seller and its Subsidiaries) has or has had,
      directly or indirectly, (i) any interest in any entity which furnished
      or sold, or furnishes or sells, services, products, or technology that
      the Company furnishes or sells, or proposes to furnish or sell, or
      (ii) any interest in any entity that purchases from or sells or
      furnishes to the Company, any goods or services.  The Company is not
      owed and does not owe any amount from or to the Related Parties
      (excluding employee compensation and other ordinary incidents of
      employment).  No property or interest in any property that is material
      to the Business as currently conducted is owned or leased by or to any
      Related Party.  All transactions pursuant to which any Related Party
      (other than the Seller and its Subsidiaries) has purchased any services,
      products, or technology from, or sold or furnished any services,
      products or technology to, the Company have been on an arms-length basis
      on terms no less favorable to the Company than would be available from
      an unaffiliated party.
    

    
        4.21  Insurance.
    

    
      The Seller maintains insurance covering the Company and the Business in
      customary forms and amounts.  There is no claim by the Company or
      Business pending under any of such policies or bonds as to which
      coverage has been questioned, denied or disputed or that the Company or
      Business has a reason to believe will be denied or disputed by the
      underwriters of such policies or bonds.  There is no pending claim of
      which its total value (inclusive of defense expenses) will exceed the
      policy limits. All premiums due and payable under all such policies and
      bonds have been paid (or if installment payments are due, will be paid
      if incurred prior to the Closing Date), and the Company and the Business
      are otherwise in material compliance with the terms of such policies and
      bonds (or other policies and bonds providing substantially similar
      insurance coverage).  The Company has not maintained, established,
      sponsored, participated in or contributed to any self-insurance plan.
    

    
        4.22  Minute Books.
    

    
      The minutes of the Company made available to the Purchaser contain
      complete and accurate records of all actions taken, and summaries of all
      meetings held, by the stockholders and the Board of Directors of the
      Company (and any committees thereof).  
    

    
        4.23  Brokers’ Fees.
    

    
      No investment banker, broker, finder, consultant or intermediary is
      entitled to any investment banking, broker, finder’s or similar fee or
      commission in connection with this Agreement or the transactions
      contemplated hereby based upon arrangements made by or on behalf of the
      Company.  
    

    
      
        

        

      

      
        
          - 35 -
        

        
          

        

      

      
        

        

      

    

    
        4.24  Accounts Receivable.
    

    
      The Company and the Business do not have any accounts receivable.
    

    
        4.25  FDA Compliance.
    

    
             (a)  The Company and the Business are not subject to any
      enforcement proceedings by the FDA and, to the Seller’s knowledge, no
      such proceedings have been threatened.  There is no civil, criminal or
      administrative action, suit, demand, claim, complaint, hearing,
      investigation, demand letter, warning letter, untitled letter or
      proceeding pending by the FDA against the Company or the
      Business.  There has not been any violation of any Seller Applicable Law
      by the Company or the Business in its submissions, record keeping and
      reports to the FDA that could reasonably be expected to require or lead
      to investigation, corrective action or regulatory enforcement
      action.  To the Seller’s knowledge, there is no civil or criminal
      proceeding relating to the Company or the Business which involves a
      matter within FDA’s jurisdiction.  To the Seller’s knowledge, no
      director, officer, employee, consultant or agent of the Company or the
      Business has: (i) made any untrue statement of material fact or
      fraudulent statement to the FDA; (ii) failed to disclose a material fact
      required to be disclosed to the FDA; or (iii) committed an act, made a
      statement, or failed to make a statement that would reasonably be
      expected to provide the basis for the FDA to invoke its policy
      respecting “Fraud, Untrue Statements of Material Facts, Bribery, and
      Illegal Gratuities,” as set forth in 56 Fed. Reg. 4691 (September 10,
      1991) or substantially similar document.  To the Seller’s knowledge, no
      director, officer, employee, consultant or agent of the Company or the
      Business has been convicted of any crime or engaged in any conduct for
      which debarment is mandated or permitted by 21 U.S.C. §335a.
    

    
             (b)  All preclinical and clinical trials in respect of the
      Business being conducted by or on behalf of the Company or the Business
      that have been submitted to any Governmental Authority, including the
      FDA and its counterparts worldwide, in connection with any Company
      Permit, are being or have been conducted in compliance in all material
      respects with the required experimental protocols, procedures and
      controls pursuant to any Seller Applicable Law, including 21 C.F.R.
      Parts 11, 50, 54, 56, 58, 812 and 814.  Neither the Company nor the
      Business have received any notices, correspondence or other
      communications in respect of the Business from the FDA requiring the
      termination or suspension of any clinical trials conducted by or on
      behalf of the Company or the Business or in which the Company or the
      Business has participated.
    

    
        4.26  Healthcare Compliance.
    

    
             (a)  To the Seller’s knowledge, neither the Company nor the
      Business has arranged with or contracted with (by employment or
      otherwise) any person who is excluded from participation in any
      Government Program for the provision of items or services for which
      payment may be made under any such Government Program.  None of the
      officers, directors, agents or managing employees (as such term is
      defined in 42 U.S.C. Section 1320a-5(b)) of the Company or the Business
      has been excluded from any Government Program or been subject to
      sanction pursuant to 42 U.S.C. Section 1320a-7a or 1320a-8 or been
      convicted of a crime described at 42 U.S.C. Section 1320a-7b.  
    

    
      
        

        

      

      
        
          - 36 -
        

        
          

        

      

      
        

        

      

    

    
        4.27  Intentionally Omitted.
    

    
        4.28  Projections; Other Representations.
    

    
      In connection with the Purchaser’s investigation of the Business, the
      Purchaser and its Affiliates may have received from or on behalf of the
      Seller and the Company certain estimates, projections or forecasts,
      including, without limitation, any projections of revenues, income from
      operations or cash flows.  The Purchaser acknowledges that there are
      uncertainties inherent in attempting to make such estimates, projections
      and forecasts, and the Purchaser is taking full responsibility for
      making its own evaluation of the adequacy and accuracy of all estimates,
      projections and forecasts and future plans so furnished or made
      available to it (including, without limitation, the reasonableness of
      the assumptions underlying such estimates, projections, forecasts and
      plans).  Accordingly, the Seller makes no representation or warranty
      with respect to such estimates, projections, forecasts and plans
      (including, without limitation, the reasonableness of the assumptions
      underlying such estimates, projections, forecasts and plans).  The
      Seller makes no other representation or warranty with respect to the
      Company or the Business except as specifically set forth in this
      Agreement.
    

    
        4.29  Representations Complete.
    

    
      None of the representations or warranties made by the Seller (as
      modified by the Seller Disclosure Schedule) in this Agreement, and none
      of the statements made in any exhibit, schedule or certificate furnished
      by the Seller pursuant to this Agreement contains any untrue statement
      of a material fact, or omits to state any material fact necessary in
      order to make the statements contained herein or therein, in the light
      of the circumstances under which made, not misleading.
    

    
      ARTICLE V   – REPRESENTATIONS AND WARRANTIES OF THE PURCHASER
    

    
      The Purchaser represents and warrants to the Seller that the statements
      contained in this Article V are true and correct.
    

    
         5.1  Organization, Qualification and Corporate Power.
    

    
      The Purchaser is duly organized, validly existing, and in good standing,
      as applicable, under the laws of the jurisdiction of its organization,
      with full corporate power and authority to conduct its business as
      currently conducted and to own and use the properties owned and used by
      it.  The Purchaser is duly qualified to do business and is in good
      standing, as applicable, in each jurisdiction in which the nature of the
      business conducted by it or property owned by it makes such
      qualification necessary, except where the failure to be so qualified or
      in good standing, as applicable, would not have a material adverse
      effect on their ability to consummate the transactions contemplated by
      this Agreement.
    

    
         5.2  Enforceability.
    

    
      All corporate action on the part of the Purchaser and its officers,
      directors and stockholders necessary for the authorization, execution,
      delivery and performance of this Agreement and the other Transaction
      Documents to which the Purchaser is a party and the performance of all
      of the Purchaser’s obligations under this Agreement and the other
      Transaction Documents to which the Purchaser is or will be a party has
      been taken or will be taken as of or prior to the Closing.  No
      additional corporate or stockholder authorization or consent is required
      in connection with the authorization, execution, delivery and
      performance of this Agreement and the other Transaction Documents to
      which the Purchaser is a party and the performance of all of the
      Purchaser’s obligations under this Agreement and the other Transaction
      Documents to which the Purchaser is or will be a party.  This Agreement
      has been, and each of the other Transaction Documents to which the
      Purchaser is a party at the Closing will have been, duly executed and
      delivered by the Purchaser, and this Agreement is, and each of the other
      Transaction Documents to which the Purchaser is or will be a party will
      be (assuming the due authorization, execution and delivery by the other
      parties hereto and thereto) at the Closing a legal, valid and binding
      obligation of the Purchaser, enforceable against the Purchaser in
      accordance with its terms, except to the extent that enforceability
      hereof may be limited by applicable bankruptcy, insolvency,
      reorganization or other similar laws affecting the enforcement of
      creditors’ rights generally and by the principles of equity regarding
      the availability of remedies.
    

    
      
        

        

      

      
        
          - 37 -
        

        
          

        

      

      
        

        

      

    

    
         5.3  No Violations; Consents.
    

    
             (a)  The execution and delivery of this Agreement and the other
      Transaction Documents by the Purchaser does not, and the performance by
      the Purchaser of its obligations under this Agreement and the other
      Transaction Documents will not: (i) conflict with or violate any
      provision of the governing documents of the Purchaser or (ii) conflict
      with or constitute a default (or an event that with notice or lapse of
      time or both would become a default) under, result in creation of any
      Lien upon any properties or assets of the Purchaser or the Company, or
      give to any Person any right of termination, amendment, acceleration or
      cancellation (with or without notice, lapse of time or both) of, any
      Contract to which the Purchaser is a party or by which any material
      properties or assets of the Purchaser is bound, result in a material
      violation of any law or any judgment, decree, order, regulation or rule
      of any court or other Governmental Authority applicable to the Purchaser
      that would materially and adversely impact the Purchaser’s ability to
      consummate the Stock Purchase or timely perform its obligations under
      this Agreement and the other Transaction Documents or that would
      materially delay the consummation of the Stock Purchase or the Delayed
      Payment.
    

    
             (b)  The execution and delivery of this Agreement and the other
      Transaction Documents by the Purchaser does not, and the performance of
      this Agreement and the other Transaction Documents by the Purchaser of
      its obligations hereunder and thereunder and the consummation of the
      transactions contemplated hereby and thereby will not, require any
      consent, approval, authorization or permit of, or filing by the
      Purchaser with or notification by the Purchaser to, any Person.
    

    
         5.4  Compliance with Law.
    

    
                The Purchaser (i) is not in conflict with, or in default or in
      violation of any decree, order or arbitration award and (ii) has not
      been in any material respect in conflict with, or in default or in
      violation of, any law, statute, rule or regulation of any Governmental
      Authority applicable to the Purchaser or by which the Purchaser is bound
      or affected (“Purchaser Applicable Law”).  The
      Purchaser has not received written notice or communication from any
      Governmental Authority alleging noncompliance with any Purchaser
      Applicable Law.  There is no judgment, injunction, order or decree of a
      Governmental Authority binding upon the Purchaser that would affect the
      transactions contemplated by or obligations under this Agreement.  The
      Purchaser has not received written notice of, and to the Purchaser’s
      Knowledge, there is no investigation of the Purchaser by any
      Governmental Authority with respect to any alleged failure or compliance
      with any Purchaser Applicable Law.
    

    
      
        

        

      

      
        
          - 38 -
        

        
          

        

      

      
        

        

      

    

    
         5.5  Brokers’ Fees.
    

    
      No investment banker, broker, finder, consultant or intermediary is
      entitled to any investment banking, broker, finder’s, or similar fee or
      commission in connection with this Agreement or the transactions
      contemplated hereby based upon arrangements made by or on behalf of the
      Purchaser.  
    

    
         5.6  Litigation.
    

    
      No Action is pending or, to the Purchaser’s Knowledge, threatened
      against the Purchaser, that questions the validity of this Agreement or
      any of the Transaction Documents to which the Purchaser is a party or
      the transactions contemplated by this Agreement or any such Transaction
      Documents, and (ii) the Purchaser is not subject to any order, writ,
      judgment, injunction, decree, determination or award that prohibits or
      restricts the transactions contemplated by this Agreement or any such
      Transaction Document.  There are no such Actions pending or threatened
      against the Purchaser that would materially and adversely impact the
      ability of the Purchaser to consummate the Stock Purchase or timely make
      the Delayed Payment.
    

    
         5.7  Independent Investigation.
    

    
      The Purchaser has conducted an independent investigation of the Business
      and the financial condition, results of operations, assets, liabilities,
      properties and prospects of the Company and, in making its determination
      to proceed with the transactions contemplated by this Agreement, the
      Purchaser has relied solely on the results of such investigation and on
      the representations and warranties of the Seller expressly set forth in Article IV
      of this Agreement, including the Seller Disclosure Schedule.
    

    
         5.8  Financial Statements; No Undisclosed Liabilities.
    

    
             (a)  The Purchaser has delivered to the Seller (i) audited
      financial statements for the fiscal-year ended December 31, 2007 and
      (ii) unaudited financial statements for the seven-months ended July 31,
      2008 (collectively, the “Purchaser Financial Statements”).  The
      Purchaser Financial Statements have been prepared in accordance with
      GAAP consistently applied during the periods covered thereby (unless as
      otherwise disclosed therein) and fairly present in all material respects
      the financial position and the results of operations of the Purchaser as
      of the dates and during the periods indicated therein, except with
      respect to the unaudited Purchaser Financial Statements for (i) normal
      year-end adjustments that are not, individually or in the aggregate,
      material, and (ii) the omission of accompanying notes and schedules.  
    

    
             (b)  Except as reflected in the Purchaser Financial Statements,
      the Purchaser has no liabilities, obligations, indebtedness, expenses,
      claims, guarantees or endorsements of any type (whether accrued,
      absolute, contingent, matured, unmatured or otherwise) that are required
      by GAAP to be set forth on the balance sheet (the “Purchaser
      Liabilities”), except for Purchaser Liabilities incurred
      since the Balance Sheet Date in the ordinary course of the business,
      consistent with past practice during the period covered by the Purchaser
      Financial Statements or that are not material.
    

    
      
        

        

      

      
        
          - 39 -
        

        
          

        

      

      
        

        

      

    

    
         5.9  Financing.
    

    
      The Purchaser has, or has (or will have) access to through one or more
      Affiliates, sufficient funds to timely make the Delayed Payment.
    

    
        5.10  Solvency.
    

    
      Immediately after giving effect to the Stock Purchase, the Purchaser
      shall be able to pay their debts as they become due.  Immediately after
      giving effect to the Stock Purchase, the Purchaser shall have adequate
      capital to carry on its business and its obligation to fund the Initial
      Capital Commitment.  No transfer of property is being made and no
      obligation is being incurred in connection with the Stock Purchase with
      the intent to hinder, delay or defraud either present or future
      creditors of the Purchaser.
    

    
        5.11  No Material Adverse Effect.
    

    
      Since July 31, 2008, the Purchaser has not had any change, development,
      fact, condition, event, occurrence or effect that, individually or in
      the aggregate, would reasonably be expected to have a material adverse
      effect on the assets, business, properties, operations, condition
      (financial or otherwise) or results of operations of the Purchaser,
      taken as a whole, or would reasonably be expected to materially delay or
      prevent the consummation of the transactions contemplated by this
      Agreement or the timely payment of the Delayed Payment.
    

    
      ARTICLE VI  – CONDITIONS TO CLOSING
    

    
         6.1  Closing Deliverables to the Purchaser.
    

    
      At the Closing, the Seller shall cause to be delivered to the Purchaser
      each of the following:
    

    
             (a)  Seller
      Closing Certificate.  The Purchaser shall have received a
      certificate dated the Closing Date and executed by a senior officer of
      the Seller addressing the accuracy of the representations and warranties
      and compliance with covenants, such certificate in form and substance
      reasonably satisfactory to the Purchaser.
    

    
             (b)  Resignation
      of Officers and Directors.  The Purchaser shall have received a duly
      executed resignation and release letter in a form reasonably
      satisfactory to the Purchaser from each of the officers and directors of
      the Company effective as of the Closing.
    

    
             (c)  Other
      Closing Deliveries.  The Seller shall have delivered to the
      Purchaser the following:
    

    
                 (i)  Secretary’s
      Certificate.  A certificate, dated as of the Closing Date, signed by
      the secretary of the Seller certifying as to (i) the incumbency of
      officers executing this Agreement and the Transaction Documents and
      (ii) the resolutions of the board of directors of the Seller authorizing
      the execution, delivery and performance by the Seller of this Agreement
      and the Transaction Documents and the consummation of the transactions
      contemplated hereby and thereby.
    

    
      
        

        

      

      
        
          - 40 -
        

        
          

        

      

      
        

        

      

    

    
                (ii)  Certification
      of Non-Foreign Status.  An affidavit from the Seller dated as of the
      Closing Date, in the form required by Treasury Regulations
      Section 1.1445-2(b)(2) and signed under penalties of perjury, stating
      that the Seller is not a foreign person for purposes of Sections 897 and
      1445 of the Code.
    

    
               (iii)  Material
      Consents.  The Seller shall have obtained and delivered to the
      Purchaser the consent to assignment of the Contracts listed on Schedule 6.1(c)(iii).
    

    
                (iv)  Certificates
      of Good Standing.  The Purchaser shall have received a long-form
      certificate of good standing from the Secretary of State of the State of
      Delaware which is dated within five (5) Business Days prior to Closing
      with respect to the Company.  The Purchaser shall have received a
      Certificate of Status of Foreign Corporation (or equivalent) of the
      Company issued by the Secretary of State of the State of Maryland dated
      within two Business Days prior to the Closing.
    

    
         6.2  Closing Deliverables of the Purchaser.
    

    
      On or at the Closing, the Purchaser shall cause to be delivered each of
      the following:
    

    
             (a)  Note.  The
      Purchaser shall have executed and delivered to the Seller the Note.
    

    
             (b)  Purchaser
      Closing Certificate.  The Seller shall have received a certificate
      dated the Closing Date and executed by a senior officer of the Purchaser
      addressing the accuracy of the representations and warranties and
      compliance with covenants, such certificate in form and substance
      satisfactory to the Seller.
    

    
             (c)  Secretary
      Certificates.  The Purchaser shall have delivered a certificate,
      dated as of the Closing Date, signed by the secretary, certifying as to
      (i) the incumbency of officers executing this Agreement and the
      Transaction Documents, and (ii) the resolutions of the board of
      directors of the Purchaser authorizing the execution, delivery and
      performance by the Purchaser of this Agreement and the Transaction
      Documents and the consummation of the transactions contemplated hereby
      and thereby.
    

    
             (d)  Waiver and
      Release Letters.  The Seller shall have received a duly executed
      waiver and release letter in a form reasonably satisfactory to the
      Seller from each of the Business Employees effective as of the Closing
      Date.
    

    
      ARTICLE VII  – COVENANTS
    

    
         7.1  Post-Closing Covenants.
    

    
      From and after the Closing Date, the parties covenant and agree as
      follows in this Section 7.1.  
    

    
             (a)  Royalty
      Payments to Seller.
    

    
      
        

        

      

      
        
          - 41 -
        

        
          

        

      

      
        

        

      

    

    
                 (i)  During the applicable Royalty Term, and until such time
      as the Purchaser’s obligation to pay royalties to the Seller is
      fulfilled in accordance with Section 7.1(a)(ix), the
      Purchaser shall pay royalties to the Seller equal to three and one-half
      percent (3.5%) of Net Sales by Purchaser and its Affiliates of (x) each
      Royalty Product sold in each country in which the sale or use of such
      Royalty Product would infringe a Valid Claim in such country, and (y)
      each Royalty Service performed in each country in which the performance
      of such Royalty Service would infringe a Valid Claim in such country
      (the “Royalty Consideration”).
    

    
                (ii)  If a Royalty Product or a Royalty Service is sold in a
      combination product or service with other components or services, Net
      Sales, for purposes of royalty payments on the combination product,
      shall be calculated by multiplying the Net Sales of that combination by
      a fraction A/B, where A is the gross selling price of the Royalty
      Product or Royalty Service sold separately and B is the gross selling
      price of the combination product or service.  If no such separate sales
      are made by the Purchaser or its Affiliates, Net Sales for royalty
      determination shall be calculated by multiplying Net Sales of the
      combination by the fraction C/(C+D), where C is the fully allocated cost
      of the Royalty Product or Royalty Service and D is the fully allocated
      cost of such other components or services.
    

    
               (iii)  The Purchaser shall furnish to the Seller a quarterly
      written report showing in reasonably specific detail the calculation of
      royalties owing for the reporting period under Section 7.1(a)(i).  If
      no royalties are payable to the Seller for the period covered by a
      report, the Purchaser shall so state in such report.  With respect to
      sales of Royalty Products and Royalty Services invoiced in United States
      dollars, all amounts shall be expressed in United States dollars.  With
      respect to sales of Royalty Products and Royalty Services invoiced in a
      currency other than United States dollars, all amounts shall be
      expressed in the domestic currency of the party making the sale together
      with the United States dollar equivalent.  The United States dollar
      equivalent shall be calculated using the average of the exchange rate
      (local currency per US$1) published in The Wall Street Journal,
      Western Edition, under the heading “Currency Trading” on the last
      business day of each month during the applicable calendar
      quarter.  Reports shall be due on the ninetieth (90th)
      day following the close of each quarter.  Purchaser shall keep complete
      and accurate records in sufficient detail to enable the royalties
      payable hereunder to be determined.
    

    
                (iv)  Royalties shown to have accrued by each royalty report
      provided for under Section 7.1(a)(iii) shall be due on the
      date such royalty report is due.  Payment of royalties in whole or in
      part may be made in advance of such due date.
    

    
                 (v)  If at any time legal restrictions prevent the prompt
      remittance of part or all royalties with respect to any country where
      the Royalty Product or Royalty Service is sold, the Purchaser shall have
      the right, in its sole discretion, to make such payments by depositing
      the amount thereof in local currency to the Seller’s account in a bank
      or other depository institution in such country.  If the royalty rate
      specified in this Agreement should exceed the permissible rate
      established in any country, the royalty rate for sales in such country
      shall be adjusted to the highest legally permissible or
      government-approved rate.
    

    
      
        

        

      

      
        
          - 42 -
        

        
          

        

      

      
        

        

      

    

    
                (vi)  The Purchaser shall be entitled to deduct the amount of
      any withholding taxes, value-added taxes or other taxes, levies or
      charges required to be withheld.  The Purchaser shall use reasonable
      efforts to minimize any such taxes, levies or charges required to be
      withheld on behalf of the Seller by the Purchaser or its
      Affiliates.  The Purchaser promptly shall deliver to the Seller proof of
      payment of all such taxes, levies and other charges, together with
      copies of all communications from or with such governmental authority
      with respect thereto.
    

    
               (vii)  Upon the written request of the Seller and not more than
      once in each calendar year, the Purchaser shall permit an independent
      certified public accounting firm of nationally recognized standing
      selected by the Seller and reasonably acceptable to the Purchaser (“Accounting
      Firm”), at Seller’s expense, to have access during normal
      business hours to such of the records of the Purchaser as may be
      reasonably necessary to verify the accuracy of the royalty reports for
      any year ending not more than twenty four (24) months prior to the date
      of such request.  The Accounting Firm shall disclose to the Seller only
      whether or not the reports are correct and the amount of any
      discrepancies.  No other information shall be shared.  If the Accounting
      Firm concludes that additional royalties were owed during such period,
      the Purchaser shall pay the additional royalties within sixty (60) days
      after the date the Seller delivers to the Purchaser the Accounting
      Firm’s written report so concluding.  The fees charged by the Accounting
      Firm shall be paid by the Seller; provided, however, if
      the audit correctly discloses that the royalties payable by the
      Purchaser for the audited period are more than one hundred ten percent
      (110%) of the royalties actually paid for such period, then the
      Purchaser shall pay the reasonable fees and expenses charged by the
      Accounting Firm.  The Seller shall treat all financial information
      subject to review under this Section 7.1(a)(vii)  as
      confidential, and shall cause the Accounting Firm to retain all such
      financial information in confidence.
    

    
              (viii)  Notwithstanding
      anything to the contrary herein, the Purchaser’s obligation to pay any
      royalties to the Seller under Section 7.1(a)(i) shall be
      fulfilled and shall irrevocably terminate and expire at such time as the
      aggregate amount paid by the Purchaser to the Seller as royalties under Section 7.1(a)(i)
      equals One Million Five Hundred Thousand Dollars ($1,500,000),
      whereafter no further royalties shall be owing by the Purchaser to the
      Seller under Section 7.1(a)(i).
    

    
             (b)  Commitment
      to Fund the Company.
    

    
                 (i)  The Purchaser shall make commercially reasonable efforts
      to fund the Company and the scientific activities of the Company with no
      less than $5,000,000 over a period of eighteen (18) months following the
      Closing Date (the “Funding”).  
    

    
                (ii)  The Funding shall be initially evidenced by a
      contribution to the Company’s operating account by the Purchaser of: (A)
      at least $350,000 within five (5) Business Days of the Closing Date; (B)
      $825,000 by October 31, 2008; and (C) $825,000 by December 31, 2008 (the
      “Initial Capital Commitment”).  The monetary
      difference between $5,000,000 and the Initial Capital Commitment may be
      funded by either the Purchaser or third-party investors, such funding
      and its form shall be accepted by the board of directors of the Company,
      at their sole discretion.
    

    
      
        

        

      

      
        
          - 43 -
        

        
          

        

      

      
        

        

      

    

    
             (c)  Continuation
      of Employee Benefits.  
    

    
                 (i)  The Seller shall be obligated to compensate each
      Business Employee for the aggregate amount of accrued but unused
      vacation or paid time-off balance for each Business Employee as of  the
      date of each Business Employee’s resignation as described in each
      Business Employee’s Resignation Letter (collectively, “PTO”).
    

    
                (ii)  The Seller agrees and acknowledges that it shall be
      solely responsible for providing continuation coverage under COBRA, and
      the applicable notices regarding such coverage, to those individuals who
      are M&A qualified beneficiaries (as defined in Treasury Regulation
      Section 54.4980B-9, Q&A-4(a)) with respect to the transactions
      contemplated by this Agreement (collectively, the “M&A
      Qualified Beneficiaries”). The Seller shall indemnify, defend
      and hold harmless Purchaser for, from and against any and all claims,
      liabilities, losses, costs and expenses (including attorney’s fees)
      relating to, arising out of, or resulting from any and all COBRA
      obligations, liabilities and claims related to M&A Qualified
      Beneficiaries and all other qualified beneficiaries (as defined in Code
      Section 4980B(g)(1)) with respect to the Seller's group health plans.
    

    
               (iii)  The Business Employees shall be eligible for such
      employee benefit plans and arrangements as other similarly situated
      employees of the Purchaser.
    

    
             (d)  Tax Matters.
    

    
                 (i)  The Seller shall prepare or cause to be prepared
      consistent with past practice in respect of the Company and file or
      cause to be filed all consolidated, combined, or unitary Tax Returns of
      the Seller or its Affiliates that include the Company, and shall pay or
      cause to be paid (and shall indemnify Purchaser against) all such Taxes
      to which such Tax Returns relate or that are attributable to a
      Pre-Closing Tax Period including any liability arising under Treasury
      Regulations Section 1.1502-6 or any similar provision of Seller
      Applicable Law and any Taxes attributable to the Section 338(h)(10)
      Elections (as defined in Section 7.1(d)(viii)(A)).  
    

    
                (ii)  The Purchaser shall prepare or cause to be prepared and
      file or cause to be filed all Tax Returns (other than Tax Returns
      described in clause (i)) for the Company for Tax periods ending on or
      before the Closing Date, and any Straddle Periods, that are required to
      be filed after the Closing Date, and shall pay or cause to be paid all
      Taxes to which such Tax Returns relate.  The Purchaser shall provide all
      such Tax Returns to the Seller for review and comment at least fifteen
      (15) days prior to the due date for filing such Tax Returns (including
      any applicable extensions), and shall consider in good faith any
      reasonable comments of the Seller with respect to such Tax Returns.  The
      Seller shall reimburse the Purchaser for all such Taxes shown on such
      Tax Returns of the Company that relate to a Pre-Closing Tax Period,
      except to the extent such Taxes resulted in an adjustment to the Initial
      Payment pursuant to Section 3.3.
    

    
               (iii)  With respect to Straddle Periods, Taxes shall be
      allocated between the period ending on the Closing Date and the period
      beginning after the Closing Date, (A) in the case of Taxes based on or
      measured by income or receipts of the Company, on the basis of an
      interim closing of the books as of the close of business on the Closing
      Date, and (B) in the case of any other Tax of the Company, pro rata on
      the basis of the number of days in such Tax period provided, that
      exemptions, allowances or deductions that are calculated on an annual
      basis (including depreciation and amortization deductions), other than
      with respect to property placed in service after the Closing
      Date,  shall be allocated between the Pre-Closing Tax Period and the
      period after the Closing Date in proportion to the number of days in
      each period.  
    

    
      
        

        

      

      
        
          - 44 -
        

        
          

        

      

      
        

        

      

    

    
                (iv)  The Purchaser, as and to the extent reasonably requested
      by the Seller, and the Seller, as and to the extent reasonably requested
      by the Purchaser, shall, and shall cause the Company to, (A) cooperate
      fully with each other in connection with, and make available to each
      other in a timely fashion, such data and other information as may
      reasonably be required for the preparation and filing of such Tax
      Returns and any audit, litigation or other proceeding with respect to
      Taxes, and (B) preserve such data and other information until the
      expiration of any applicable limitation period with respect to Taxes to
      which such data or information relates.  The Seller shall control the
      conduct of, through its counsel, any audit or administrative or judicial
      proceeding involving any Taxes for which the Seller would have exclusive
      liability hereunder (either directly or by way of indemnification); provided,
      however, that the Seller shall not settle any audit or proceeding
      with respect to Taxes that could have the effect of increasing the Tax
      liability of the Purchaser for any Post-Closing Tax Period of the
      Company without the prior written consent of the Purchaser (which shall
      not be unreasonably withheld, delayed or conditioned), except as
      required by law.  The Purchaser shall control all other audit or
      administrative or judicial proceedings with respect to Taxes of the
      Company or in respect of the Business, including, without limitation,
      with respect to any Straddle Period.  The Purchaser shall not (and shall
      not cause or permit the Company to) file any amended return for any
      Pre-Closing Tax Period without the written consent of the Seller (which
      shall not be unreasonably withheld, delayed or conditioned), except as
      required by law.  Notwithstanding anything to the contrary herein, in
      the event of a conflict between the procedures set forth in this Section 7.1(d)(iv)
      and Section 8.3(b), the provisions of this Section 7.1(d)(iv)
      shall govern.
    

    
                 (v)  The amount of any Tax refund of the Company for any Tax
      period ending on or before the Closing Date shall be for the account of
      the Seller to the extent Seller previously paid the Taxes with respect
      to such refund, except to the extent such refund was taken into account
      in computing Final Working Balance pursuant to Section 3.2.  The
      amount of any Tax refund of the Company for any Tax period beginning
      after the Closing Date shall be for the account of the Purchaser.  The
      amount of any Tax refund of the Company for any Straddle Period shall be
      equitably apportioned between the Purchaser and the Seller in accordance
      with the allocation of such Taxes under clause (iii).
    

    
                (vi)  All transfer, documentary, sales, use, stamp and
      registration Taxes incurred in connection with the purchase and sale of
      the Shares (collectively, “Transfer Taxes”) shall be
      paid by the Seller when due.  The party responsible for filing Tax
      Returns with respect to such Transfer Taxes by Seller Applicable Law or
      Purchaser Applicable Law, as applicable, shall cause to be filed all
      such Tax Returns and other documentation and, if required by Seller
      Applicable Law or Purchase Applicable Law, as applicable, the non-filing
      party shall join in the execution of any such Tax Returns and other
      documentation.
    

    
      
        

        

      

      
        
          - 45 -
        

        
          

        

      

      
        

        

      

    

    
               (vii)  All Tax sharing agreements or similar agreements with
      respect to or involving the Company, if any, shall be terminated as of
      the Closing Date and, shall have no further effect.
    

    
              (viii)  Section
      338(h)(10) Elections.
    

    
                      A.  At the written request of the Purchaser, the
      Purchaser and Seller shall make a timely, irrevocable and effective
      election under Section 338(h)(10) of the Code and any similar election
      under any applicable state, local or foreign income Tax law
      (collectively, the “Section 338(h)(10) Elections”)
      with respect to the Purchaser’s acquisition of the Company.
    

    
                      B.  If the Purchaser elects to make the Section
      338(h)(10) Elections, the Purchaser shall deliver to the Seller, at
      least thirty (30) days prior to the due date for filing of the Section
      338(h)(10) Elections (the “Due Date”), drafts of
      Internal Revenue Service Form 8023 and any similar forms under
      applicable state, local and foreign income Tax law (collectively, the “Forms”).  The
      Seller shall review such Forms and provide any proposed revisions to the
      Purchaser at least fifteen (15) days prior to the Due Date.  The
      Purchaser and Seller agree to negotiate in good faith with respect to
      such proposed revisions and to attempt to resolve any differences
      between the parties.  The Forms, in the form reasonably agreed by the
      parties, shall be duly and timely executed by the Purchaser and
      Seller.  If the Purchaser elects to make the Section 338(h)(10)
      Elections, the Purchaser shall duly and timely file the Forms as
      prescribed by Treasury Regulation Section 1.338(h)(10)-1 or the
      corresponding provisions of applicable state, local or foreign income
      Tax law.
    

    
                      C.  If
      the Purchaser elects to make the Section 338(h)(10) Elections, at least
      thirty (30) days prior to the due date and filing of Internal Revenue
      Service Form 8883 by either party, the Purchaser shall provide the
      Seller with a draft of Internal Revenue Service Form 8883 (including the
      calculation and proposed allocation of the Aggregate Deemed Sales Price
      in a manner consistent with the requirements of Section 338 and the
      Treasury Regulations thereunder).  The Seller shall review such Form
      8883 and provide any proposed revisions to the Purchaser at least ten
      days prior to the due date of such Form 8883 for either party.  The
      Purchaser and Seller agree to negotiate in good faith with respect to
      such proposed revisions and to attempt to resolve any differences
      between the parties.  In the event the parties reach agreement as to the
      information to be reflected on such Form 8883, the Form 8883 shall be
      revised and timely filed by each party as required by law.  Each of
      Purchaser and Seller shall report the allocation of the Aggregate Deemed
      Sales Price (and any adjustments thereto) for Tax purposes and file its
      Tax Returns (including the Form 8883) in a manner consistent with any
      mutually-agreed allocations determined pursuant to this Section
      7.1(d)(viii).  In the event that the parties do not reach agreement
      on the information to be reflected on the Form 8883, each party shall
      provide to the other party its final version of its Form 8883and shall
      timely file its final version of such Form 8883 in the manner required
      by law.
    

    
             (e)  Further
      Assurances.  Each of the parties hereto shall execute such further
      documents, and perform such further acts, as may be reasonably necessary
      by it to consummate the transactions contemplated hereby, on the terms
      herein contained, and to otherwise comply with the terms of this
      Agreement and consummate the transactions contemplated by this Agreement
      and the other Transaction Documents.  In furtherance of the foregoing,
      (a) on or before the Closing, the Seller shall consummate and carry out
      in full all of the assignments and transfers contemplated under that
      certain Assignment and Assumption Agreement between the Seller and the
      Company dated as of September 15, 2008, and (b) at any time and from
      time to time after the Closing, at the Purchaser’s reasonable request
      and without further consideration therefor, the Seller shall take such
      actions as may reasonably be necessary by it in order to transfer,
      convey, assign and deliver to the Purchaser or the Company, as
      applicable, in or to, all of the assets and properties of the Business
      as operated by the Company immediately prior to the Closing, consistent
      with this Agreement and such Assignment and Assumption Agreement, and
      otherwise to fulfill the Seller’s obligations under this Agreement and
      such Assignment and Assumption Agreement.  In addition, without limiting
      the generality of the foregoing, at or promptly following the Closing,
      upon the request of the Purchaser, the Seller (on behalf of itself and
      its Affiliates) shall take such actions as may reasonably be necessary
      in order to obtain, or to enable the Purchaser and/or the Company to
      obtain, all consents and waivers from third parties required in order to
      assign to and vest in the Company or the Purchaser any rights,
      obligations or warranties under any Material Contracts pertaining to the
      Company or the Business, including without limitation under the Material
      Contracts listed in Schedule 7.1(e).  Further, the Seller agrees
      and covenants that the Seller shall continue to comply in full with all
      ongoing obligations under the Asset Purchase Agreement between Gene
      Logic Inc., Ocimum Biosolutions Limited and Ocimum Biosolutions Inc.
      dated October 14, 2007, as amended, including without limitation the
      non-competition agreement set forth in Section 4.14(b) thereof, and the
      Transition Services Agreement between Gene Logic Inc. and Ocimum
      Biosolutions Inc., dated December 14, 2007.
    

    
      
        

        

      

      
        
          - 46 -
        

        
          

        

      

      
        

        

      

    

    
             (f)  Access.  In
      order to facilitate the resolution of any third party claims made by or
      against or incurred by the Seller or the Company with respect to the
      period prior to the Closing, after the Closing, upon reasonable notice,
      the Purchaser or the Seller, as the case may be, shall (a) afford the
      Seller or the Purchaser, as the case may be, and their respective agents
      and representatives reasonable access, during normal business hours, to
      the offices, properties, books and records of the Company and the
      Business related solely to such period prior to the Closing, and (b)
      furnish to the Seller or the Purchaser, as the case may be, and its
      agents and representatives such additional financial and other
      information regarding the Company and the Business related solely to
      such period prior to the Closing as the Seller or the Purchaser, as the
      case may be, may from time to time reasonably request; provided,
      however, that such investigation shall be conducted in a manner so as
      not to disrupt or interfere with or damage any of the businesses or
      operations of the Seller, the Purchaser or the Company and in no event
      shall the Seller, the Company or the Purchaser be required to provide
      access to any information which might constitute a waiver of the
      attorney-client or similar privilege.
    

    
             (g)  Unaudited
      Quarterly Financial Statements; Financial Records.  The Seller shall
      use commercially reasonable efforts to prepare unaudited financial
      statements and financial data for the period from November 28, 2007 to
      September 12, 2008, reviewed by Ernst & Young or its affiliates in
      accordance with Statement of Auditing Standards No. 100 (collectively,
      the “Post-Closing Financial Statements”).  Promptly
      following the Closing, the Seller shall commence work preparing the
      Post-Closing Financial Statements, which shall be delivered to the
      Purchaser promptly following the Closing, and in any event within three
      (3) months following the Closing Date.  The Seller shall pay for the
      first $10,000 of expenses in connection with the preparation of the
      Post-Closing Financial Statements and such expenses in excess of $10,000
      shall be borne equally by the Purchaser and the Seller.  The Seller
      shall preserve and retain all records, including all financial records,
      policies and procedures customarily required for the completion of an
      audit by an independent accounting firm, in its and its Affiliates
      possession (the “Financial Records”) following the
      Closing and through completion of the audit contemplated by this
      subparagraph (g), and shall provide the Purchaser access to all such
      Financial Records, and to its financial personnel and independent
      accounting firm, at the Purchaser’s expense, at reasonable times upon
      reasonable notice until completion of such audit.  Thereafter, Seller
      shall deliver the Financial Records to the Purchaser; provided, however,
      that Seller may retain a copy of the Financial Records for its
      files.  In furtherance and not in limitation of the obligations set
      forth in this Section 7.1(g), Seller shall not take any actions
      or omit to take any actions with the intent of preventing Ernst & Young
      or its affiliates from providing its or their consent for Purchaser to
      include such Post-Closing Financial Statements in any registration
      statement or other document or report to be filed by the Purchaser with
      the U.S. Securities and Exchange Commission.
    

    
      
        

        

      

      
        
          - 47 -
        

        
          

        

      

      
        

        

      

    

    
             (h)  Confidentiality.  From
      and for three (3) years after the Closing, the Seller and its Affiliates
      shall keep secret and retain in confidence (in a manner consistent with
      Seller’s protection of its proprietary information, but in any event
      using not less than reasonable care), and shall not use for the benefit
      of itself or others, all confidential matters relating to the Business
      or the Company obtained prior to the Closing, and shall not disclose any
      of the foregoing to anyone outside of the Purchaser and its Affiliates, provided,
      however, this covenant shall not apply to any information which
      is or becomes generally available to the public other than as a result
      of disclosure by the Seller or its Affiliates or to the extent
      such a disclosure is, in Seller’s judgment, required by the laws, rules
      or regulations of the U.S. Securities and Exchange Commission.  The
      Seller shall have the right to disclose the foregoing to the extent so
      required in any legally required government or securities filings, legal
      proceedings, subpoena, civil investigative demand or other similar
      process (provided the Seller (A) except to the extent legally
      prohibited, provides the Purchaser with prompt notice of such required
      disclosure so the Purchaser may attempt to obtain a protective order
      (and in the case of securities law filings, obtain exemptive relief from
      disclosure), (B) cooperates with the Purchaser, at the Purchaser ‘s
      expense, in obtaining such protective order or exemptive relief, and
      (C) only discloses that information which he or it is absolutely
      required to disclose as advised by counsel).  Notwithstanding the
      foregoing, with respect to any Company Intellectual Property maintained
      by the Company as a trade secret, the provisions of this Section 7.1(h)
      shall survive for as long as Company maintains such Company Intellectual
      Property as a trade secret.
    

    
             (i)  Intellectual
      Property Matters.
    

    
                 (i)  To the extent the conduct of the Business by the Company
      immediately following the Closing Date (consistent with how the Business
      is being currently conducted) infringes any Intellectual Property right
      of the Seller or its Affiliates existing prior to and subsisting after
      the Closing Date, the Seller (on behalf of itself and its Affiliates)
      hereby irrevocably waives and agrees never to assert such Intellectual
      Property rights against the Purchaser, its Affiliates and their
      successors in interest to such Intellectual Property rights.
    

    
      
        

        

      

      
        
          - 48 -
        

        
          

        

      

      
        

        

      

    

    
                (ii)  At the Closing, the Company shall be in the possession
      of complete and correct copies of all Company Confidential Information
      (including all commented versions to the extent the same exist) and user
      and technical documentation related to the Company Products, as the same
      exists as of the Closing Date.  
    

    
               (iii)  Following the Closing, the Seller and its Affiliates
      will not use the www.diogenix.com domain name.  
    

    
             (j)  Company
      Office Space.  The Company may utilize the Company Office Space
      until September 30, 2008 at no additional charge to the Company or the
      Purchaser, with the consent of Ocimum Biosolutions Inc. (the “Sublessor”).  The
      Seller further agrees to reasonably work with the Sublessor to arrange
      for Company to enter into a sublease between the Company and Sublessor,
      provided that the Seller shall have no material ongoing liability as a
      result of such sublease.  
    

    
         7.2  Non-Competition Agreement.
    

    
      During the period beginning on the date hereof and ending on the date
      that is the three (3) year anniversary of the Closing Date (the “Restricted
      Period”), neither the Seller nor any of its Affiliates shall,
      without the prior written consent of the Purchaser, design, develop,
      distribute or sell molecular diagnostic products that compete with the
      Business, as and in the manner in which it is conducted, or proposed to
      be conducted in the Company’s business plan dated as of June 2008, by
      the Company as of the Closing Date, in any country, province, state,
      city or other political subdivision of the world in which the Business
      operates or otherwise distributes, licenses or sells related products or
      services during the Restricted Period.  Notwithstanding the previous
      sentence, nothing in this Section 7.2 shall be deemed to restrict
      the Seller or any of its Affiliates from designing, developing,
      distributing or selling molecular diagnostic products that do not
      infringe upon the Company’s Registered Intellectual Property, assuming
      that the claims in the Company’s Registered Intellectual Property have
      been granted as filed as of the Closing Date, including but not limited
      to Seller’s activities around the potential development or
      commercialization of molecular diagnostic assets that are not derived
      from the Company’s Intellectual Property in any country, province,
      state, city or other political subdivision of the world.  
    

    
         7.3  Employee Non-Solicitation Agreement.
    

    
      During the one-year period following the Closing Date, neither the
      Seller nor the Purchaser shall, and each shall cause its respective
      Subsidiaries or Affiliates not to, hire or solicit the employment or
      engagement of services of any employee of the other party or any of its
      Subsidiaries without the prior written consent of the party for whom
      such employees are employed.  For purposes of the prior sentence: (i)
      any general solicitation for employment (including general solicitation
      via the internet, newspaper advertisements and the like) that may be
      targeted to a particular geographical or technical area but that are not
      targeted towards specific employees; (ii) the employment of any party’s
      employee who contacts the other party or its Subsidiaries on his or her
      own initiative and without any direct or indirect solicitation by the
      hiring party.
    

    
         7.4  Miscellaneous.
    

    
      The Purchaser and the Seller acknowledge that the restrictions contained
      in Sections 7.2 and 7.3 are reasonable and necessary
      to protect the legitimate interests of the other party and constitute a
      material inducement to both parties to enter into this Agreement and
      consummate the transactions contemplated by this Agreement.  The parties
      acknowledge that any violation of Sections 7.2 (by the Seller)
      and 7.3 (by either party) will result in irreparable injury and
      that the injured party shall be entitled to seek preliminary and
      permanent injunctive relief, without the necessity of proving actual
      damages, which rights shall be cumulative and in addition to any other
      rights or remedies to which such party may be entitled.
    

    
      
        

        

      

      
        
          - 49 -
        

        
          

        

      

      
        

        

      

    

    
      ARTICLE VIII  – SURVIVAL OF REPRESENTATIONS, WARRANTIES AND
      COVENANTS; INDEMNIFICATION
    

    
         8.1  Survival.
    

    
      All representations and warranties of the Seller in Article IV
      of this Agreement or in the certificates delivered pursuant to Section 6.1
      shall survive until the first anniversary of the Closing Date; provided,
      however, that the representations and warranties in Sections 4.1
      (Organization, Qualification and Corporate Power), 4.2
      (Enforceability), 4.6 (Capitalization), and 4.15 (Tax
      Matters) shall survive until, and shall terminate upon, 90 days after
      the expiration of the applicable statute of limitations with respect to
      the liability in question; and, provided, further, that
      the representations and warranties in Section 4.11
      (Intellectual Property) and Section 4.12 (Material Contracts) shall
      survive until, and shall terminate upon, the third anniversary of the
      Closing Date or the expiration or termination date of the last Contract
      listed in Schedule 4.12(a) to terminate or expire.  All
      representations and warranties of the Purchaser in Article V or
      in the certificates delivered pursuant to Section 6.2 shall
      survive until the later to occur of (i) payment of the Delayed Payment
      or (ii) the first anniversary of the Closing Date; provided, however,
      that the representations and warranties in Sections 5.1
      (Organization, Qualification and Corporate Power), and 5.2
      (Enforceability) shall survive until, and shall terminate upon, 90 days
      after the expiration of the applicable statute of limitations with
      respect to the liability in question.  The covenants and agreements to
      be performed after Closing set forth in this Agreement, including those
      set forth in Section 7.1, shall survive the Closing and
      continue until all obligations with respect thereto shall have been
      performed or satisfied or shall have been terminated in accordance with
      their terms.  
    

    
         8.2  Seller’s Indemnification.
    

    
             (a)  Subject to the limitation set forth in this Article VIII,
      from and after the Closing Date, the Seller shall indemnify the
      Purchaser and its officers, directors, stockholders, Affiliates,
      successors and assigns (the “Purchaser Indemnified Parties”)
      for and hold them harmless from any and all claims, liabilities, losses,
      damages, Taxes, costs and expenses, including reasonable fees and
      disbursements of counsel and consultants and including any such
      reasonable out-of-pocket expenses incurred in investigating, defending
      against or settling any of the foregoing (collectively, “Losses”),
      suffered or incurred by the Purchaser Indemnified Parties, related to or
      arising out of: (i) any breach or inaccuracy of any representation and
      warranty made by the Seller to the Purchaser in this Agreement; (ii) any
      failure by the Seller to perform or comply with any covenant in or
      obligation under this Agreement; (iii) any Funded Indebtedness
      outstanding as of the Closing (other than as a result of any financing
      arranged by the Purchaser); and (iv) any Pre-Closing Employee
      Liabilities.
    

    
      
        

        

      

      
        
          - 50 -
        

        
          

        

      

      
        

        

      

    

    
             (b)  The Indemnifying Party (as defined below) shall not have any
      right of contribution, indemnification or right of advancement from the
      Purchaser or the Company with respect to any Loss claimed by a Purchaser
      Indemnified Party.
    

    
         8.3  Purchaser’s Indemnification
    

    
             (a)  Subject to the limitation set forth in this Article VIII,
      from and after the Closing Date, the Purchaser shall indemnify the
      Seller and its officers, directors, stockholders, Affiliates, successors
      and assigns (the “Seller Indemnified Parties”, and
      collectively with the Purchaser Indemnified Parties, an “Indemnified
      Party”) for and hold them harmless from any and all Losses,
      suffered or incurred by the Seller Indemnified Parties, related to or
      arising out of: (i) any breach or inaccuracy of any representation and
      warranty made by the Purchaser to the Seller in this Agreement; and
      (ii) any failure by the purchaser to perform or comply with any covenant
      in or obligation under this Agreement.
    

    
             (b)  The Indemnifying Party (as defined below) shall not have any
      right of contribution, indemnification or right of advancement from the
      Seller with respect to any Loss claimed by a Seller Indemnified Party.
    

    
         8.4  Claims.
    

    
             (a)  Notice and
      Determination of Claims.  An Indemnified Party seeking
      indemnification hereunder, whether or not the applicable dollar amount
      limitations specified in Section 8.5 have been exceeded,
      shall promptly notify the Purchaser or the Seller, as the case may be,
      (sometimes referred to in this Article VII as the “Indemnifying
      Party”) in writing (the “Claim Notice”)
      of any claim, action, suit, proceeding, demand or breach (collectively,
      a “Claim”) with respect to which the Indemnified
      Party claims indemnification hereunder.  Any Claim Notice delivered
      under this Section 8.4 shall describe in reasonable detail
      the facts and circumstances on which the asserted indemnification Claim
      is based, specify the amount of such indemnification Claim if then
      ascertainable and, if not then ascertainable, the estimated amount
      thereof, shall specify the basis for indemnification pursuant to this
      Agreement.  After receipt of the Claim Notice, the Indemnified Party and
      the Indemnifying Party shall first attempt to negotiate in good faith a
      written resolution of such disputed Claim within a period not to exceed
      sixty (60) days from the date of receipt of a request for such
      negotiation.  Such negotiations shall be conducted by officers of each
      of the Indemnifying Party and the Indemnified Party who have
      authorization to resolve such disputed Claim.  In the event the
      Indemnifying Party and the Indemnified Party cannot negotiate a written
      resolution to such disputed Claim during such sixty (60) day negotiation
      period, the disputed Claim will be resolved in accordance with this
      Agreement.  A failure by the Indemnified Party to
      deliver a Claim Notice shall not relieve the Indemnifying Party of its
      obligations under this Article VIII except to the extent, if
      at all, that such Indemnifying Party shall have been materially
      prejudiced thereby and except as set forth in Section 8.5(a).
    

    
             (b)  Third Party
      Claims.
    

    
                 (i)  If any Claim against the Indemnified Party is made by or
      in respect of a third party (a “Third Party Claim”),
      the Indemnified Party shall promptly after receiving notice of such
      Third Party Claim, deliver to the Indemnifying Party a Claim Notice,
      accompanied by copies of all documents and information relevant to the
      Third Party Claim and in the Indemnified Party’s possession.
    

    
      
        

        

      

      
        
          - 51 -
        

        
          

        

      

      
        

        

      

    

    
                (ii)  Upon written notice to the Indemnified Party within
      thirty (30) days after receipt of the Claim Notice, the Indemnifying
      Party shall have the right to direct, through counsel of its own
      choosing, the defense or settlement of any Third Party Claim at its own
      expense.  If the Indemnifying Party elects to direct the defense of any
      Third Party Claim, the Indemnified Party shall not pay, or permit to be
      paid, any part of any claim or demand arising from such asserted
      liability unless the Indemnifying Party consents in writing to such
      payment (which consent shall not be unreasonably withheld or delayed) or
      unless the Indemnifying Party, withdraws from the defense of such
      asserted liability, or unless a final judgment from which no appeal may
      be taken by or on behalf of the Indemnifying Party is entered against
      the Indemnified Party for such liability.  The Indemnifying Party shall
      keep the Indemnified Party timely apprised of the status of such Third
      Party Claim.  The Indemnified Party shall retain the right to employ its
      own counsel and to participate, at its own expense, in the defense or
      handling of any Third Party Claim, the defense of which has been assumed
      by the Indemnifying Party pursuant hereto.
    

    
               (iii)  If there is a Third Party Claim that, if adversely
      determined would give rise to a right of indemnification for Losses
      under this Article VIII, then any amounts incurred, paid or
      accrued in defense or settlement of such Third-Party Claim, regardless
      of the outcome of such Third Party Claim, shall be deemed to be Losses
      that were actually sustained, suffered or incurred by the Indemnified
      Party for purposes of the indemnification obligations of the
      Indemnifying Party set forth in this Article VIII.  If the
      Indemnifying Party does not give written notice to the Indemnified Party
      within thirty (30) days after receipt of the Claim Notice of a Third
      Party Claim that the Indemnifying Party has elected to assume the
      defense of such Third Party Claim or if the Indemnifying Party shall
      fail to defend or, if after commencing or undertaking any such defense,
      shall fail to prosecute or shall withdraw from such defense, the
      Indemnified Party shall have the right to undertake the defense or
      settlement thereof, at the Indemnifying Party’s expense.  If the
      Indemnified Party assumes the defense of any Third Party Claim pursuant
      to this Section 8.4(b)(iii) and proposes to settle such
      Third Party Claim prior to a final judgment thereon or to forgo any
      appeal with respect thereto, then the Indemnified Party shall give the
      Indemnifying Party prompt written notice thereof, and the Indemnifying
      Party shall have the right to participate in the settlement or assume or
      reassume the defense of such Third Party Claim.  If the Indemnified
      Party assumes the defense of a Third Party Claim pursuant to the terms
      of this Section 8.4(b)(iii), the Indemnified Party shall
      keep the Indemnifying Party timely apprised of the status of such Third
      Party Claim and shall, subject to this Section 8.4(b)(iii),
      not settle such Third Party Claim without the prior written consent of
      the Indemnifying Party (which shall not be unreasonably delayed or
      withheld).  If an Indemnified Party defends or handles such Third Party
      Claim, the Indemnifying Party shall be entitled to participate in the
      defense or handling of such Third Party Claim with its own counsel and
      at its own expense.
    

    
                (iv)  In connection with any defense of a Third Party Claim,
      each of the parties to this Agreement shall, and shall use commercially
      reasonable efforts to cause their respective controlled Affiliates to,
      cooperate in the defense or prosecution thereof and to in good faith
      retain and furnish such records, information and testimony, and attend
      such conferences, discovery proceedings, hearings, trials and appeals,
      as may be reasonably requested by any other party in connection
      therewith.
    

    
      
        

        

      

      
        
          - 52 -
        

        
          

        

      

      
        

        

      

    

    
         8.5  Limitations; Exclusive Remedy; Effect of Investigation;
      Waiver.
    

    
      The obligations set forth in this Article VIII are subject
      to the following limitations:
    

    
             (a)  Claim Notice.  No
      Indemnifying Party shall be obligated to defend and hold harmless any
      Indemnified Party, or otherwise be liable to such Indemnified Party,
      with respect to any indemnification claim made by the Indemnified Party
      pursuant to Section 8.2(a) or Section 8.3(a), as
      applicable, unless a Claim Notice with respect to such indemnification
      claim shall have been delivered to the Indemnifying Party prior to the
      expiration of the survival period for such claim specified in Section 8.1
      above.
    

    
             (b)  Deductible
      Basket; Maximum Liability.  The Indemnified Parties shall not be
      entitled to indemnification for any Losses pursuant to Section 8.2(a)
      or Section 8.3(a), as applicable, unless and until such time as
      the cumulative aggregate amount of all indemnifiable Losses exceeds
      $25,000 (the “Deductible Basket”), after which the
      Indemnified Parties shall be entitled to recover only for amounts in
      excess of the Deductible Basket.  The aggregate maximum amount of Losses
      for which the Indemnified Parties are entitled to indemnification
      pursuant to Section 8.2(a) or Section 8.3(a), as
      applicable, shall be limited to $250,000 (the “Cap”).  The
      Deductible Basket and the Cap shall not apply to any Claims based upon
      fraud or breaches of the Seller’s representations in Sections 4.1
      (Organization, Qualification and Corporate Power), 4.2
      (Enforceability), 4.6 (Capitalization), 4.15 (Tax Matters)
      and 4.23 (Brokers’ Fees) or of Purchaser’s representations in
      Sections 5.1 (Organization, Qualification and Corporate Power), 5.2
      (Enforceability), and 5.5 (Brokers’ Fees).  
    

    
             (c)  Calculation
      of Losses.  Any payments to the Indemnified Parties pursuant to Section 8.2
      or Section 8.3, as applicable, shall be limited to the amount of
      any Losses that remain after deducting therefrom any insurance,
      indemnity, contribution or other similar payments actually recovered by
      the Purchaser, the Company or any of their respective Affiliates from
      any third party with respect thereto (net of all related costs).  Any
      payments to the Indemnified Parties pursuant to Section 8.4 shall
      be limited to the amount of any Losses that remain after deducting
      therefrom any insurance, indemnity, contribution or other similar
      payments actually recovered by the Seller or any of its respective
      Affiliates from any third party with respect thereto (net of all related
      costs).
    

    
             (d)  Effect of
      Investigation; Waiver.  An Indemnified Party’s right to
      indemnification or other remedies based upon the representations and
      warranties of the Seller will not be affected by any investigation of
      the Indemnified Party.  Such representations and warranties shall not be
      affected or deemed waived by reason of the fact that the Indemnified
      Party should have known that any representation or warranty might be
      inaccurate.  Any investigation by the Purchaser or Seller shall be for
      its own protection only and shall not affect or impair any right or
      remedy of the Purchaser or Seller.
    

    
      
        

        

      

      
        
          - 53 -
        

        
          

        

      

      
        

        

      

    

    
             (e)  Exclusive
      Remedy; Consequential and Other Special Damages.  
    

    
                 (i)  Each of the Indemnified Parties hereby acknowledges and
      agrees that, following the Closing, its sole and exclusive remedy with
      respect to any and all Losses relating to the subject matter of this
      Agreement, other than any Losses arising from the fraud of the Seller or
      for Taxes pursuant to Section 7.1(b), shall be pursuant to
      the indemnification provisions set forth in this Article VIII.  This
      Section 8.5(e)(i) will not limit any party’s right to seek
      equitable or injunctive relief.
    

    
                (ii)  In
      no event shall any indemnifying party be liable for special, indirect,
      incidental, punitive or consequential damages; provided, however,
      that the parties acknowledge and agree that for purposes of this Article
      VIII, any damages actually paid to a third party in respect of a
      Third Party Claim shall be considered direct damages rather than
      special, indirect, incidental, punitive or consequential damages, and
      shall therefore constitute indemnifiable Losses hereunder.
    

    
             (f)  Adjustment
      to Purchase Price.  All payments made pursuant to this Article VIII
      shall be deemed adjustments to the Purchase Price for Tax and all other
      purposes.
    

    
             (g)  No Right of
      Set-Off.  No Indemnified Party may set-off any claim for
      indemnification or otherwise against the Delayed Payment or the Note.
    

    
      ARTICLE IX  – MISCELLANEOUS
    

    
         9.1  Expenses.
    

    
      Subject to Section 3.2 and Section 7.1(g) and
      regardless of whether the transactions contemplated by this Agreement
      are consummated and unless otherwise expressly set forth in this
      Agreement, each party to this Agreement shall pay its own expenses
      incurred in connection with this Agreement and the transactions
      contemplated hereby; the parties acknowledging that prior to Closing,
      expenses of the Company in connection with this Agreement and the
      transactions contemplated hereby are expenses of the Seller.  
    

    
         9.2  Publicity.
    

    
      The Purchaser agrees that immediately after the execution and delivery
      of this Agreement and immediately after the Closing the Seller, after
      consultation with the Purchaser, may issue a press release concerning
      this Agreement and the Closing, as the case may be, and, within four
      Business Days of the execution of this Agreement, file a report on
      Form 8-K with the U.S. Securities and Exchange Commission disclosing the
      entry into this Agreement and attaching a copy of this Agreement.
    

    
         9.3  Notices.
    

    
      Any notice, request or demand desired or required to be given hereunder
      shall be in writing given by personal delivery, confirmed facsimile
      transmission or overnight courier service, in each case addressed as
      respectively set forth below or to such other address as any party shall
      have previously designated by such a notice.  The effective date of any
      notice, request or demand shall be the date of personal delivery, the
      date on which successful facsimile transmission is confirmed or the date
      actually delivered by a reputable overnight courier service, as the case
      may be, in each case properly addressed as provided herein and with all
      charges prepaid.
    

    
      
        

        

      

      
        
          - 54 -
        

        
          

        

      

      
        

        

      

    

    
    	
          To the Purchaser or, after the Closing, the Company:
        
	
           
        	
          Nerveda, Inc.
        
	

        	
          3888 Quarter Mile Drive
        
	

        	
          San Diego, CA 92130
        
	

        	
          Attention: Chief Executive Officer
        
	
          
            with a copy to:
          

        
	

        	
          Wilson Sonsini Goodrich & Rosati, P.C.
        
	

        	
          12335 El Camino Real, Suite 200
        
	

        	
          San Diego, California 92130
        
	

        	
          Fax: (858) 350-2399
        
	

        	
          Attention: Martin J. Waters
        
	
          To the Seller:
        
	

        	
          Ore Pharmaceuticals Inc.
        
	

        	
          610 Professional Drive
        
	

        	
          Gaithersburg, MD 20879
        
	

        	
          Attention: General Counsel
        

    

    
         9.4  Headings.
    

    
      The headings contained in this Agreement are intended solely for
      convenience and shall not in any way affect the meaning or
      interpretation of this Agreement.
    

    
         9.5  Seller Deliverables.
    

    
      When a Section of this Agreement provides that an item has been made
      available for inspection or delivered to the Purchaser, such obligation
      of the Seller will have been satisfied if an electronic copy of such
      item was delivered to the Purchaser and its Representatives.
    

    
         9.6  Entire Agreement; Amendments.
    

    
      This Agreement, including any exhibits hereto and the Seller Disclosure
      Schedule, and the Transaction Documents constitute the entire agreement
      of the parties with respect to the subject matter hereof and thereof and
      supersede any and all prior understandings, written or oral, between the
      parties, or any of them, with regard to the subject matter hereof and
      thereof.  This Agreement may not be amended, modified or waived orally,
      but only by an instrument in writing signed by an authorized
      representative of each of the parties hereto.
    

    
         9.7  Severability.
    

    
      If any term or other provision of this Agreement is invalid, illegal or
      incapable of being enforced by any rule of law, or public policy, all
      other conditions and provisions of this Agreement shall nevertheless
      remain in full force and effect so long as the economic or legal
      substance of the transactions contemplated hereby is not affected in any
      manner adverse to any party.  Upon such determination that any term or
      other provision is invalid, illegal or incapable of being enforced, the
      parties hereto shall negotiate in good faith to modify this Agreement so
      as to effect the original intent of the parties as closely as possible
      in a mutually acceptable manner in order that the transactions
      contemplated hereby be consummated as originally contemplated to the
      fullest extent possible.
    

    
         9.8  Waiver.
    

    
      
        

        

      

      
        
          - 55 -
        

        
          

        

      

      
        

        

      

    

    
      Waiver of any term or condition of this Agreement by any party hereto
      shall be effective if in writing and shall not be construed as a waiver
      of any subsequent breach or failure of the same term or condition or any
      other terms or conditions of this Agreement.  No waiver shall be
      effective unless it is in writing signed by an authorized representative
      of the waiving party.
    

    
         9.9  Binding Effect; Assignment.
    

    
      This Agreement shall be binding upon, and shall be enforceable by and
      inure to the benefit of, the parties and their respective successors and
      assigns; provided, however, that neither this Agreement
      nor any rights or obligations of a party hereunder may be assigned or
      transferred by operation of law or otherwise by such party without the
      prior written consent of the other parties, and any attempted assignment
      of this Agreement or any of such rights or obligations without such
      consent shall be void and of no effect.  Notwithstanding the foregoing,
      (a) the indemnification and other rights hereunder of a party may be
      assigned as collateral to any lender of such party or any its
      Affiliates, (b) any party may assign its rights and obligations
      hereunder to an Affiliate, and (c) any party may assign its rights and
      obligations hereunder in connection with a sale of all or substantially
      all of its assets, business or securities, provided that, in any case,
      such assignment shall not relieve the assigning party of its obligations
      under this Agreement.
    

    
        9.10  No Third Party Beneficiaries.
    

    
      Nothing in this Agreement shall confer any rights or liabilities upon
      any Person that is not a party to this Agreement, except as expressly
      provided hereunder.
    

    
        9.11  Specific Performance.  
    

    
      The parties to this Agreement agree that irreparable damage would occur
      in the event that the parties do not consummate the Stock Purchase in
      accordance with the specific terms of this Agreement.  It is accordingly
      agreed that the parties to this Agreement shall be entitled to an
      injunction or injunctions to prevent breaches of this Agreement and to
      enforce specifically the terms and provisions of this Agreement in order
      to cause the Stock Purchase to be consummated in any court of the United
      States or any state having jurisdiction, this being in addition to any
      other remedy to which they are entitled at law or in equity.
    

    
        9.12  Counterparts.
    

    
      This Agreement may be executed and delivered (including by facsimile
      transmission) in one or more counterparts, and by the different parties
      hereto in separate counterparts, each of which when executed and
      delivered shall be deemed to be an original but all of which taken
      together shall constitute one and the same agreement.  
    

    
        9.13  Governing Law.
    

    
      This Agreement shall be governed by and construed in accordance with the
      laws of the State of Delaware, applicable to agreements made and to be
      performed entirely within such State, without regard to the conflict of
      laws principles thereof
    

    
        9.14  Consent to Jurisdiction and Venue.
    

    
      ANY ACTION INVOLVING THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED
      HEREBY SHALL BE BROUGHT AND MAINTAINED SOLELY IN THE COURT OF CHANCERY
      OF THE STATE OF DELAWARE.  EACH OF THE PARTIES HERETO (I) IRREVOCABLY
      CONSENTS TO THE EXCLUSIVE JURISDICTION AND VENUE OF THE COURT OF
      CHANCERY IN THE STATE OF DELAWARE, IN CONNECTION WITH ANY MATTER BASED
      UPON OR ARISING OUT OF THIS AGREEMENT OR THE MATTERS CONTEMPLATED HEREIN
      AND IRREVOCABLY CONSENTS TO THE SERVICE OF THE SUMMONS AND COMPLAINT AND
      ANY OTHER PROCESS IN ANY OTHER ACTION OR PROCEEDING RELATING TO THE
      TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, ON BEHALF OF ITSELF OR ITS
      PROPERTY, BY THE PERSONAL DELIVERY OF COPIES OF SUCH PROCESS TO SUCH
      PARTY (PROVIDED, THAT, THE FOREGOING SHALL NOT AFFECT THE RIGHT OF ANY
      PARTY TO SERVE LEGAL PROCESS IN ANY OTHER MANNER PERMITTED BY LAW) AND
      WAIVES AND COVENANTS NOT TO ASSERT OR PLEAD ANY OBJECTION WHICH THEY
      MIGHT OTHERWISE HAVE TO SUCH JURISDICTION, VENUE AND SUCH PROCESS AND
      (II) AGREES NOT TO COMMENCE ANY LEGAL PROCEEDINGS RELATED HERETO EXCEPT
      IN SUCH COURTS. THE PARTIES AGREE THAT FOR THE PURPOSE OF ENFORCING THE
      COVENANTS IN THIS AGREEMENT, THE PARTIES MAY APPLY DIRECTLY TO ANY COURT
      OF COMPETENT JURISDICTION WHEREVER LOCATED FOR A TEMPORARY RESTRAINING
      ORDER, INJUNCTION OR INJUNCTIVE RELIEF OR OTHER INTERIM OR CONSERVATORY
      RELIEF, AS NECESSARY, TO ENFORCE THE COVENANTS IN THIS AGREEMENT WITHOUT
      BREACH OF THIS PROVISION AND WITHOUT ABRIDGEMENT OF THE POWERS OF THE
      DELAWARE COURTS.
    

    
      
        

        

      

      
        
          - 56 -
        

        
          

        

      

      
        

        

      

    

    
        9.15  Waiver of Jury Trial.
    

    
      EACH OF THE PURCHASER AND THE SELLER HEREBY IRREVOCABLY WAIVES ALL RIGHT
      TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER
      BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS
      AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREBY OR THE ACTIONS OF
      PURCHASER AND THE SELLER IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE
      AND ENFORCEMENT HEREOF.
    

    
      9.16  Other Remedies. Except as otherwise set
      forth herein, any and all remedies herein expressly conferred upon a
      party will be deemed cumulative with and not exclusive of any other
      remedy conferred hereby, and the exercise by a party of any one right or
      remedy hereunder will not preclude the exercise of any other right or
      remedy.
    

    
      9.17  Interpretation. The words “include,”
      “includes” and “including” when used herein shall be deemed in each case
      to be followed by the words “without limitation.”  The table of contents
      and headings contained in this Agreement are for reference purposes only
      and shall not affect in any way the meaning or interpretation of this
      Agreement.
    

    
      9.18  Rules of Construction. The parties hereto
      agree that they have been represented by counsel during the negotiation
      and execution of this Agreement and, therefor, waive the application of
      any law, regulation, holding or rule of construction providing that
      ambiguities in an agreement or other document will be construed against
      the party drafting such agreement or document.
    

    
      [Signatures appear on following page]
    

    
      
        

        

      

      
        
          - 57 -
        

        
          

        

      

      
        

        

      

    

    
      IN WITNESS WHEREOF, the parties hereto have entered into and signed this
      Stock Purchase Agreement as of the date and year first above written.
    

    
      

    

    
    	
           
        	
          
            ORE PHARMACEUTICALS INC.
          

        	

        
	

        	

        	
           
        
	

        	
          By:
        	
          
            /s/ Philip L. Rohrer Jr.
          

        	

        
	

        	
          Name:
        	
          
            Philip L. Rohrer Jr.
          

        	

        
	

        	
          Title:
        	
          
            Chief Financial Officer
          

        	

        
	

        	

        	
           
        
	

        	

        	
           
        
	

        	
          
            NERVEDA, INC.
          

        	

        
	

        	

        	
           
        
	

        	
          By:
        	
          
            /s/ Cam Gallagher
          

        	

        
	

        	
          Name:
        	
          
            Cam Gallagher
          

        	

        
	

        	
          Title:
        	
          
            President and Chief Executive Officer
          

        	

        

    

    

    

    

    

    

    

    

    

    

    

    
      -58-Exhibit 10.1
    

    

    

    
      September 12, 2008
    

    

    

    
      Richard D. Crowley
[Address]
[Address]
    

    
      

      Dear Rick:
    

    
      Integrated Device Technology, Inc. (“IDT”)
      is pleased to make you an offer
      of employment as Vice President
      and Chief Financial Officer
      reporting to Ted Tewksbury, President and Chief Executive Officer.  The
      terms of your employment are as follows:
    

    
    	
           
        	
          Salary:
        	
          $325,000.00 annually; payable biweekly
        
	
           
        
	

        	
          Status:
        	
          Full time / Exempt
        
	
           
        
	

        	
          Stock Options:
        	
          
            You will be recommended for a stock option grant to purchase
            200,000 shares of IDT common stock, which will vest over a four
            year period, assuming your continued service to IDT. The granting
            of your stock options will occur on or about the 15th day of the
            month following the completion of the month in which you begin
            employment with IDT, subject to approval by our Board of
            Directors. Your stock options will have a per share exercise price
            equal to the closing price of IDT common stock on the last workday
            prior to the date of grant.
          

        
	
           
        
	

        	
          Restricted Stock Units (RSUs):
        
	
           
        
	

        	

        	
          
            You will be recommended for a Restricted Stock Unit grant of
            15,000 shares of IDT common stock, which will vest over a four
            year period, assuming your continued service to IDT. The granting
            of your RSUs will occur on or about the 15th day of the month
            following the completion of the month in which you begin
            employment with IDT, subject to approval by our Board of Directors.
          

        
	
           
        
	

        	
          Annual Bonus:
        	
          You will be eligible for participation in our incentive compensation
          plan for FY09 (March 31, 2008-March 29, 2009). Your participation
          will be at an annual target of 60% of your base earnings. This
          fiscal year’s bonus will be pro-rated in accordance with the FY09
          Incentive Compensation Plan for Exempt Employees, herewith enclosed.
        
	
           
        
	

        	
          Sign-On Bonus:
        	
          You will be eligible for a one-time $50,000 Sign-On Bonus, minus
          applicable State and Federal taxes. Payment of Sign-On Bonus
          requires signature on attached Sign-On Bonus Agreement
        
	
           
        
	

        	
          Benefits:
        	
          You will be eligible for our full range of employee benefits
          including medical, dental, vision, life, disability, and 401(k). You
          will also earn four (4) weeks of vacation per year. A summary of our
          benefit program is attached.
        

    

    
      
        

        

      

      
        

        

        
          

        

      

      
        

        

      

    

    
      This offer is pending acceptable reference
      qualification and background verification.  In addition, IDT requires
      each candidate for employment to submit to a drug test which will be
      administered through an independent laboratory.  Your employment is
      contingent upon you successfully passing a pre-employment drug screen.
    

    
      On your start date, you agree to execute
      IDT’s standard form of Employee Confidentiality and Invention Agreement,
      providing for protection of IDT’s proprietary information and trade
      secrets.
    

    
      Employment with IDT is at the mutual
      consent of the employee and IDT.  Accordingly, you and IDT retain the
      right to terminate the employment relationship at will, at any time,
      with or without cause.  Please understand that no representative of IDT
      other than the Chief Executive Officer has the authority to make any
      contrary agreement or representation, and that such agreement made by
      the Chief Executive Officer must be in writing and signed by you and the
      Chief Executive Officer.
    

    
      In order to comply with the Immigration
      Reform and Control Act of 1986, this offer is contingent upon you
      providing proof of eligibility to work in the United States.  Be
      prepared to supply the original documents containing this information on
      your start date.
    

    
      This letter contains a complete statement
      of all the arrangements between you and IDT with respect to your
      employment by IDT, this letter supersedes all prior and existing
      negotiations and agreements between us concerning your employment, and
      can only be changed or modified pursuant to a written instrument duly
      executed by each of the parties hereto.
    

    
      Because of the responsibilities associated
      with this position, it is essential that our office receive your
      decision by September 16, 2008.  At
      that time we will discuss your availability date and reporting
      procedures.  Your target start date is Monday,
      October 20, 2008.
    

    
      Should you wish to discuss this offer or
      inform us of your decision regarding this offer, please call me at (408)
      284-8401.  I
      am confident that you can expect a challenging and rewarding career as a
      member of our company.  We look forward to your acceptance of our offer.
    

    

    

    
      Sincerely,
    

    
      /s/ Theodore L. Tewksbury III
Theodore
      L. Tewksbury III
President
      and Chief Executive Officer
    

    

    

    
      /s/ Richard D. Crowley, Jr.
Candidate
      Signature of Acceptance
    

    

    

    
      September 15, 2008
Date
    

    
      
        

        

      

      
        
          2
        

        
          

        

      

      
        

        

      

    

    

    

    
      Attachments:
Benefits
      Summary
Change
      of Control Agreement
Indemnification
      Agreement
Employee
      Confidentiality and Invention Agreement
    

    

    

    

    

    

    

    

    

    
      3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00147-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00147-of-00352.parquet"}]]